Biophysical and mutational analysis of gp41-mediated membrane fusion and its inhibition by Suntoke, Tara R
HIV Entry:
A Biophysical and Mutational Analysis of gp4 1-mediated
Membrane Fusion and Its Inhibition
By
Tara R. Suntoke
B.S. Biology
Carnegie Mellon University
Submitted to the Department of Biology in Partial Fulfillment of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY
at the
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
June 2005
C 2005 Massachusetts Institute of Technology
All rights reserved.
MASSACHUSETS INSTITUTE
OF TECHNOLOGY
LRAR IES iIBRARI  
Signature of Author:
Certified by:
Certified by:
Accepted by:
V Department of Biology
May 20, 2005
Peter S. Kim
Former Professor, Department of Biology
President, Merck Research Laboratories
Thesis Co-Supervisor
'rew L .Dvid- -C. C
David C. Chan
Professor, Department of Biology
California Institute of Technology
Thesis Co-Supervisor
Stephen P. Bell
Professor, Department of Biology
Chairman, Biology Graduate Committee
_ _ __
MUHIVES1-1..
Acknowledgments
I thank my parents, Russ and Ava, for their continual support and encouragement. Twenty three
years ago, they made the bold decision to leave India and move to the United States in search of
better opportunities for their children and themselves. From then until now, they have given us
the world. I truly appreciate their hard work, dedication, generosity, and love. I also thank my
sister and brother, Amy and Jamshed, for their constant support and companionship.
I am grateful for the encouragement that Peter Kim gave me during my early years of graduate
school. I appreciate and admire his big-picture thinking and his rigorous approach to science. I
learned a tremendous amount from the graduate students, post-docs, and technicians in the Kim
lab, and I thank them for their thoughtful suggestions and help.
I thank David Chan for giving me the opportunity to continue my thesis work in his lab.
Throughout my time at Caltech, David has guided my research projects, helped me to analyze and
interpret results, and has offered invaluable advice when I was publishing and writing this thesis.
He has always had an open-door policy and has been willing to discuss any of my concerns. I
appreciate his advice, patience, and efforts in helping me complete my thesis work. I also thank
all the Chan lab members, past and present, who have been great labmates, friends, and co-
workers.
My committee members, Rick Young, Harvey Lodish, and Bob Sauer, have been instrumental in
my progress, and it is through their suggestions that I have been able to carry out successful
projects. I am grateful for their input and encouragement.
Finally, Erik, I can't thank you enough for so many things-your unwavering support,
encouragement, advice, friendship, and love.. .just to name a few. You've kept me sane through
this whole thing, you make me laugh, you're always up for a trip or a movie, and you are always
caring, generous, and considerate. You helped me to believe that I can do this. Thank you so
much for everything. I truly value our time together, and can't wait to take the next step,
wherever that may be!
2
HIV Entry:
A Biophysical and Mutational Analysis of
gp41-mediated Membrane Fusion and Its Inhibition
By
Tara R. Suntoke
Submitted to the Department of Biology on May 20, 2005
in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in Biology
Abstract
The experiments described in this thesis were designed to elucidate the manner in which the
HIV-1 envelope protein (Env) initiates infection of host cells, and to develop inhibitors of viral
entry. Env comprises two non-covalently attached subunits, gpl20 and gp41, that associate as a
trimer on the virion surface. Once gp 120 contacts the target cell, gp41 undergoes extensive
conformational changes to mediate fusion of viral and cellular membranes. First, a short
hydrophobic stretch of residues at the gp4 1 N-terminus insert into the target membrane,
anchoring the protein in both viral and cellular membranes. This 'prehairpin' intermediate
structure exposes an N-terminal a-helical coiled coil that is the target of promising antiviral
peptides and small molecules. A previously unstudied region of N-terminal trimer was stabilized
by fusion to a trimeric scaffold peptide and biophysically characterized (Chapter 2). This hybrid
peptide itself potently inhibited HIV fusion, and the basis for this inhibition was assessed by
studying mutant molecules. Efforts to use this peptide as an immunogen to elicit anti-gp41
antibodies are also outlined. Similar design strategies may be useful in developing N-terminal
peptide inhibitors and HIV vaccine candidates, and in screening for antiviral molecules that bind
to this region. As fusion progresses, the prehairpin intermediate resolves into a hairpin structure.
This critical transition involves interaction of the N-terminal coiled coil with the gp41 C-terminal
region. Evidence suggests that this N-C association provides the energy necessary to promote
juxtaposition and merging of viral and cellular membranes. This hypothesis was tested using a
biophysical and cell biological approach (Chapter 3), in which residues essential for this
transition were mutated and analyzed. These studies confirm the hypothesis and highlight the
importance of specific hydrophobic and polar contacts between the N- and C- terminal gp41
regions. This work contributes to a detailed understanding of the gp41 fusion machinery;
furthermore, it shows that such knowledge can be used to design effective viral entry inhibitors.
Finally, Chapter 4 places this work in the context of a broad overview of current drug and vaccine
developments, and addresses some of the significant challenges that confront HIV researchers.
Thesis Supervisors:
Dr. Peter S. Kim, Former Professor of Biology, MIT
(Current Title: President, Merck Research Labs)
Dr. David C. Chan, Professor of Biology, California Institute of Technology
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CHAPTER 1
INTRODUCTION: HIV-1 MEMBRANE FUSION
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HIV- 1 is the etiological agent of the acquired immunodeficiency syndrome (AIDS) pandemic.
The virus is a member of the Retrovirus family and the Lentivirus genus. As a retrovirus, HIV-1
contains a single-stranded RNA genome that is converted to DNA by the viral enzyme reverse
transcriptase and inserted into the host genome. As a lentivirus, HIV-1 is able to infect
nondividing cells and causes prolonged, but ultimately fatal, disease progression.
HIV research, from basic biology of the virus to vaccine trials, is fueled by an incentive
even greater than scientific knowledge: the desire to prevent, or at least reduce, human disease
and suffering caused by this deadly virus. The work in this thesis involves cell biological and
biophysical studies of HIV-1 gp41, the viral protein responsible for fusing viral and cellular
membranes and thereby initiating infection. This chapter serves as an introduction to the biology
of HIV-1 replication, and a summary of the vast body of work detailing the entry of this virus into
host cells. Chapter 2 describes an attempt to generate a novel vaccine candidate, in which a
portion of the gp41 ectodomain was stabilized as a hybrid protein, biophysically characterized,
and injected into guinea pigs. Along the way, this molecule was also examined for its viral
inhibitory activity, and subsequent studies led to the generation of a nanomolar inhibitor of HIV- 1
entry. Chapter 3 illustrates a biophysical and mutagenic approach to understanding the
mechanism by which gp41 mediates fusion. These studies provide further insight into the
membrane fusion process and the mechanism of action of entry inhibitors and drug-resistant
viruses. Finally, in Chapter 4, current advancements in drug and vaccine research as well as
some of the challenges facing HIV researchers today are examined.
Virion structure and genomic organization
The HIV-1 genome (Figure 1A) encodes three major polyproteins that are common to all
retroviruses: Gag, Pol, and Env. Gag, a polyprotein that is cleaved into matrix (MA), capsid
(CA), and nucleocapsid (NC), and Env are structural genes. The viral enzymes protease (PR),
reverse transcriptase (RT), and integrase (IN) are encoded by the Pol precursor protein. The virus
also contains the regulatory proteins Tat and Rev, as well as the accessory proteins Vif, Vpr, Vpu,
and Nef. The function of these proteins in the lifecycle is discussed below.
Approximately 120 nm in diameter, the HIV-1 virion contains at its center two single-
stranded RNA molecules coated with viral NC proteins. This core and the trio of viral enzymes,
6
PR, RT, and IN, are enclosed within a cage of structural CA and MA proteins. The outermost
shell of the virus consists of the envelope protein, Env, embedded in a lipid bilayer.
HIV-1 Lifecycle
The HIV-1 lifecycle (Figure B) begins with attachment of the virion to target cells expressing
surface CD4 and one of two chemokine receptors, CCR5 or CXCR4. This stage, as well as the
subsequent fusion of viral and cellular membranes, is mediated by gpl20 and gp41, the non-
covalently-associated subunits of the HIV envelope glycoprotein (Env) (for a review of the HIV
lifecycle see (23), (13)).
Upon entering the host cell, the virion is partially uncoated to reveal the genomic RNA
and viral RT begins synthesis of double-stranded DNA. The nucleoprotein preintegration
complex (PIC), containing some Gag and Pol proteins as well as cellular factors, transports this
nascent DNA through the cytoplasm and into the nucleus. The accessory protein Vpr is also
involved in this transport. Active nuclear import by the PIC machinery gives viral nucleic acid
access to nondividing cells arrested in the G1 phase of the cell cycle-a feature unique to
lentiviruses. The accessory protein Vif, or viral infectivity factor, is highly conserved among
lentiviruses. Vif functions to allow viral replication in otherwise non-permissive cells, at a step
that follows viral entry and precedes DNA integration (23).
Insertion of DNA into the host genome is mediated by the integrase protein. The site of
integration plays a significant role in determining the expression pattern of the provirus and in
creating deleterious mutations within the host genome. This step completes the early phase of the
viral lifecycle, in which viral proteins perform the majority of the essential functions.
The subsequent late phase is catalyzed primarily by cellular enzymes that perform their
normal transcription and translation functions. Viral regulatory proteins and cellular transcription
factors contribute to viral RNA synthesis. Tat stimulates expression from the viral long terminal
repeat (LTR) by binding to a stem-loop structure in the LTR (called TAR) and enhancing the
processivity of RNA Polymerase II. Early transcripts leave the nucleus fully spliced. Later,
unspliced and singly spliced mRNA variants are exported from the nucleus by the viral regulatory
protein Rev.
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Cellular machinery translates viral messages in the cytoplasm. The structural (Gag) and
enzymatic (Pol) proteins that are enclosed in the virion, along with full-length genomic RNA,
associate in patches of plasma membrane that contain specific lipid content (9, 38). Env is
transported through the secretory pathway and is inserted in the plasma membrane, where it
associates with newly forming viral particles. The viral accessory protein Vpu prevents
premature interaction between Env and its cellular receptor protein CD4 in the endoplasmic
reticulum by binding to CD4 and causing its degradation. The importance of Nef, another
accessory protein, in in vitro studies is debated. However, Nef is necessary to generate high titers
of virus in HIV-infected patients. This protein also downregulates cell-surface expression of
CD4, the viral receptor, and the major histocompatibility complex I (MHC I) (23).
As the virion assembles at the plasma membrane, it induces membrane curvature that
allows it to bud off the plasma membrane. This particle is initially non-infectious and is known
as an immature virion. The action of viral protease to cleave the Gag and Pol precursor proteins
results in internal structural reorganization to form the mature, infectious virion.
Envelope processing
The envelope glycoprotein (Env) is synthesized from singly spliced viral mRNA. Upon
translation, the 160 kilodalton Env precursor, gp160, is translocated into the rough endoplasmic
reticulum where it is glycosylated, forms disulfide bonds, and oligomerizes (17, 53). gp160 is
then transported into the Golgi network, where cellular furin-like proteases cleave the precursor
into two non-covalently attached subunits, gp120 and gp41 (28). This proteolytic cleavage is
essential for Env function. The receptor-binding subunit, gp 120, is anchored to the viral
membrane by its association with the transmembrane glycoprotein gp4 1. Since this interaction is
relatively weak, a substantial portion of gpl20 is shed from the virion or infected cell surface.
The Env glycoprotein is a trimer on the virion surface (8, 46, 48).
Env is heavily glycosylated (gp 120 has 24 potential N-linked glycosylation sites and
gp41 has five) and contains several disulfide bonds (nine within gp120 and one within gp41)
(Figure 2A and Appendix 1). Extensive glycosylation of gp 120, the subunit most exposed on the
virion surface, permits the virus to evade the host immune response.
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gp41 architecture
gp41 contains several important subdomains (Figure 2A) and requires proteolytic cleavage of the
Env precursor in order to properly function. A stretch of approximately twenty hydrophobic
amino acids at the newly created amino terminus is termed the fusion peptide. This region is
followed by two amphipathic helical domains, called the N-terminal heptad repeat (N-HR or N-
helix) and C-terminal heptad repeat (C-HR or C-helix), that are linked by a short disulfide-
bonded loop. The C-HR domain is followed by the transmembrane segment (TM), and a long
intraviral portion called the cytoplasmic tail.
Fusion model
gp120 initiates infection by binding to cells expressing CD4, a cell-surface marker for a subset of
T cells, macrophage, and other phagocytic cells. Subsequent binding of gp 120 to its coreceptor,
CXCR4 or CCR5, (both members of a family of chemokine receptors with seven membrane-
spanning domains), triggers a series of conformational changes in gp41, which facilitates the
merging of viral and cellular membranes.
The current model for gp4 1-mediated membrane fusion involves the interaction and
conformational changes of several of its distinct domains (14, 19, 26, 44). Upon gpl20-receptor
interaction, the gp41 N-terminal fusion peptide is released from its native state contacts and
inserts into the target cell membrane. A prehairpin intermediate then forms, in which the N-
terminal helices form a trimeric coiled coil and gp41 is extended between the viral and target cell
membranes. This structure collapses into a trimer-of-hairpins, with C-terminal helices packing in
an antiparallel manner into the conserved grooves between adjacent N helices, which represents
the fusion-active core ofgp41 (Figure 2, B and C). Formation of this six-helix bundle pulls the
amino and carboxy termini of the gp41 ectodomain into close proximity. The resulting
juxtaposition of viral and cellular membranes leads to membrane fusion.
The six-helix bundle structure is intimately linked to fusion. However, although its
formation is thought to provide the energy required to fuse lipid bilayers, the exact mechanism by
which this occurs remains unknown. Several models have been proposed. One suggests that
trimer-of-hairpins formation could occur concurrently with the merging of lipid bilayers and thus
directly provide the energy required for membrane fusion (2). In 1999, Baker and colleagues
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solved the structure of the paramyxovirus F (fusion) protein core from simian virus type 5 (SV5).
They found that at the N-terminus of the N-peptide, the coiled coil extends into the putative
fusion peptide (FP) in a continuous, relatively inflexible, a-helical structure. At the C-terminus
of the C-peptide, the seven residues between the crystallized core and the transmembrane domain
(TM) were deleted and found to be unnecessary for F glycoprotein function. These results were
interpreted to indicate that flexible regions adjacent to the FP and TM domains are not essential
for the fusion machinery. Furthermore, they suggested that membranes may merge concurrently
with six-helix bundle formation.
In the case of the influenza hemagglutinin 2 (HA2) fusion protein, several residues from
the N-terminus of the N trimer form a cap at the end of the coiled coil, ending the helical
conformation well before the fusion peptide (44). Thus, in the case of this well-characterized
orthomyxovirus, a flexible linker adjacent to the FP and TM domains could theoretically allow
opposing membranes to remain apart even after trimer-of-hairpins formation.
The merging of lipid bilayers and mixing of viral and cellular contents are proposed to
occur through another gp41 intermediate, termed hemifusion, and formation of a fusion pore.
Studies with influenza HA suggest that several six-helix bundles interact with each other at the
fusion site to create an initial fusion pore (5, 15, 37). Electrophysiological measurements show
that a small, flickering pore eventually expands and allows passage of viral contents into the
target cell (12, 24, 45). Hemifusion is a potential intermediate between six-helix bundle
formation and full fusion, occurring immediately prior to initial pore formation. The intermediate
consists of mixed outer (i.e. opposing) leaflets of the viral and target cell membranes-the inner
leaflets remain intact and keep viral and cellular contents separate. As the fusion pore enlarges,
the inner leaflets of each bilayer merge, thus completing the fusion process (reviewed in (19, 26)).
While hemifusion has not been observed under normal circumstances using currently available
techniques, HA containing TM truncations (1), TM replacement by a GPI anchor (30), and a
point mutation in the FP domain (39) displays a hemifusion phenotype. The first example of
retroviral hemifusion was recently reported for Moloney murine leukemia virus (MoMLV). A
point mutation in the receptor-binding subunit caused lipid but not content mixing of dye-labeled
virions and target cells, although lipid mixing for the mutant was delayed when compared to
wild-type (55). To date, no such observation has been made for HIV.
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Structures of viral fusion proteins
At least three distinct conformations of the gp41 envelope glycoprotein have been proposed: the
native or pre-fusogenic state, the prehairpin intermediate, and the fusion-active or fusogenic state.
Several lines of evidence suggest that the trimer-of-hairpins structure is not present in the native
or prehairpin conformations of the envelope glycoprotein. First, a comparison of pre- and post-
fusogenic HA2 structures from influenza virus demonstrates that large conformational changes
upon exposure to low pH trigger six-helix bundle formation (44). In fact, in the native state
structure, only a portion of the N-terminal region of HA2 is helical. Second, peptide inhibitors
derived from the HIV gp41 core are likely to inhibit fusion in a dominant negative manner by
preventing trimer-of-hairpins formation (7, 18). The extreme thermostability of the six-helix
bundle strongly suggests that once formed, it will not dissociate; thus, the mechanism of action of
inhibitory peptides supports the hypothesis that the trimer-of-hairpins structure is not present until
a late stage in the fusion pathway (25, 31, 32). Third, it is predicted that fusion proteins will
adopt the lowest energy conformation when folded in the absence of the receptor binding protein.
Indeed, in the absence of HA 1, the receptor binding subunit of influenza, HA2 folds into the
fusogenic trimer-of-hairpins structure (19).
Although no retroviral native state structure has yet been solved, structures of the fusion-
active cores of several viruses provide much insight into the mechanism of viral membrane
fusion. Remarkably, the core structures of retroviruses (e.g. HIV, simian immunodeficiency virus
(SIV), MoMLV), orthomyxoviruses (influenza), paramyxoviruses (SV5, human respiratory
syncytial virus), filoviruses (Ebola), and coronaviruses (SARS-CoV) (14, 19, 54) all reveal the
same antiparallel six-helix bundle conformation. This striking similarity implies an evolutionary
conservation of the fusion machinery.
In the fusion-active structure of HIV- 1 gp4 1, the N-terminal helices form a trimeric
coiled coil (Figure 2C). C-terminal helices pack into the grooves between adjacent N-helices in
an antiparallel manner. The structure of the gp41 core also reveals a large hydrophobic cavity on
the surface of the N-terminal trimer that forms a docking site for three C-terminal residues.
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Cavity-containing or cavity-binding inhibitors of infection
X-ray crystal structures of the gp4l core have identified critical contacts between N and C-
terminal helices (8, 46, 48). This interface is lined with predominantly hydrophobic residues that
are among the most highly conserved within gp4 1. Peptides derived from the N- or C-terminal
helices (termed N or C peptides) are potent inhibitors of HIV-l infection, acting in a dominant
negative manner to prevent formation of the gp41 six-helix bundle. These peptides include
enfuvirtide, or T20, (27), the first FDA-approved viral entry inhibitor used to fight HIV-1
infection, several N peptides (4, 18, 33, 52), and a trimer-of-hairpins derivative, called 5-Helix,
which lacks one C helix and presumably inhibits infection by sequestering the C-terminal region
ofgp41 (40). The inhibitory activity of a potent C peptide, C34, depends largely on its ability to
form critical contacts within the N-terminal hydrophobic cavity (7). Furthermore, small peptides
(20, 43) and synthetic molecules (21) that bind selectively to this coiled-coil cavity also inhibit
fusion. A detailed summary of HIV inhibitors, including those that prevent viral entry, is
included in Chapter 4.
Mutagenesis of the gp41 trimer-of-hairpins
A vast amount of work describing mutagenesis of gp41 exists in the literature. While some
mutants appear to function normally, many affect gp4 1-gp 120 interaction or alter gp41 fusion
activity. Since a mutagenic approach to studying gp41 function was taken in this work (Chapters
2 and 3), a review of the relevant mutations is helpful to understanding the basis for mutant
selection.
Table 1 is a representative list of several categories ofgp41 mutants. Since the gp41
fusion-active core structure was determined in 1997, researchers have biophysically characterized
peptide complexes derived from the N- and C-HR regions in order to dissect gp41 function.
Table 1 includes a summary of the core structure stability for each set of mutants, if such work
has been published. Cell biological and mutagenesis experiments, coupled with these
investigations of core stability, have led to an emerging hypothesis correlating the strength of
interhelical (i.e. between N- and C-helices) packing interactions with gp41 fusion activity.
The gp41 mutants in Table 1 are divided into six categories. The first represents
mutations that have no effect on gp41 function, indicating that, most likely, these residues do not
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make critical contacts in the native state or the six-helix bundle structure (reviewed in (41)). The
following two categories represent mutants with abnormal precursor processing or Env
presentation on the viral surface. It is therefore expected that these mutants are fusion-impaired
(10, .1 1, 35, 47, 51). Mutations that result in a weak trimer-of-hairpins structure often decrease
gp41-mediated fusion, as seen in the fourth category (3, 6, 22, 29, 34-36, 49, 51). Since we are
interested specifically in mutations that affect gp41 function at the stage oftrimer-of-hairpins
formation, these mutants are particularly intriguing. Similarly, there is one category-containing
the only example of such a mutant in the literature-in which increased trimer-of-hairpins
stability is correlated with an increase in fusogenicity (6, 42). Mutations in the sixth and final
group were created in the N-HR to abolish interaction between N- and C-helices (16, 49, 50).
While trimer-of-hairpins stability was never tested for these mutants, it is a likely explanation of
their impaired gp41 function.
Finally, a review of Table 1 reveals that position within gp41 does not dictate the
function of a particular residue. Furthermore, the nature of the substitution significantly affects
the phenotype of the mutant, as seen with the different substitutions of the isoleucine residue at
position 573 (1573).
These mutagenesis experiments strengthen the model for viral membrane fusion, in
which trimer-of-hairpins formation drives membrane merger. However, it is difficult to
effectively compare the results of these studies. The variety of cell types used for cell-cell fusion
experiments, the methods of scoring syncytia, the nature of the substitutions (hydrophobic, polar,
conservative, or nonconservative), and the recombinant trimer-of-hairpins peptides used to assess
core stability vary considerably. Thus, a systematic and rigorous analysis of hairpin mutants,
especially those that affect N-C interaction, would be a useful addition toward understanding how
the gp41 fusion machinery functions. Identifying important N-C contacts could lead to the design
of improved fusion inhibitors, and may uncover specific subdomains within gp41 that have
unique roles in membrane fusion.
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Figure 1. Viral genome and lifecycle.
(A) .HIV-1 genomic organization. Expression of viral genes is driven from the long terminal
repeat (LTR), a repeated motif that is also essential for reverse transcription of viral DNA and for
genomic integration. The HIV Gag proteins are synthesized as a single polyprotein precursor,
Pr55, that is cleaved to generate the matrix (MA), capsid (CA), and nucleocapsid (NC) proteins.
Downstream of Gag is Pol, a highly conserved region of the genome that encodes the viral
enzymes protease (PR), reverse transcriptase (RT), and integrase (IN). The envelope protein
(Env) is synthesized from a bicistronic Vpu/Env mRNA. Env mediates viral entry into the host,
while Vpu assists in viral budding and intracellular CD4 degradation. In contrast to simple
retroviruses that only encode Gag, Pol, and Env, HIV contains several regulatory and accessory
proteins. Tat is required for efficient transcription of viral genes, and Rev facilitates nuclear
export of unspliced or singly-spliced viral RNA. The accessory proteins, Vif, Vpr, Vpu, and Nef,
were initially thought to be dispensable for viral replication, but this view is changing following
more recent in vivo experiments. Vif may either increase viral infectivity or may allow
productive infections of otherwise nonpermissive cell types. Vpr functions early in the viral
lifecycle, most likely in transport of the viral genome to the nucleus. Surprisingly, Vpu is only
present in HIV- 1 and not the closely-related HIV-2 or SIV. Vpu enhances virus budding and
degrades cellular CD4. Nef also has similar functions, and appears to be required for disease
induction in vivo.
(B) Viral lifecycle. Interaction of HIV Env with the CD4 receptor and a chemokine coreceptor
(CCR5 or CXCR4) on the target cell surface triggers the first step in the viral lifecycle: fusion of
viral and target cell membranes. Exposure of the virion core to the cytoplasm initiates reverse
transcription of the viral RNA genome; this process occurs four to eight hours after infection. A
complex of viral and cellular proteins then transports the viral nucleic acid to the nucleus, where
it is stably integrated into the host genome. Expression of the provirus is driven off the viral long
terminal repeat (LTR) sequence, with the help of viral accessory proteins. Translation and
processing of the Env precursor occurs in the rough ER and Golgi, while other viral proteins
(such as Gag and Pol) are synthesized on free ribosomes in the cytoplasm. Virion assembly
occurs at the cell surface, and budding of the viral particle initially yields an immature, non-
infectious virus. Viral protease then cleaves precursor structural proteins, which causes
rearrangement of these proteins within the virion and yields mature, infectious virus.
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Figure 2. Env architecture and fusion model.
(A) Important subdomains within the Env glycoprotein (not drawn to scale). gpl20 contains five
variable domains (V1-V5) that are marked with hatched boxes and are interspersed with five
constant domains (C 1-C5). These domains indicate sequences that readily mutate (variable) and
ones that remain relatively unchanged (constant) among diverse HIV-1 isolates. In addition,
there are 24 N-linked glycosylation sites and nine disulfide bonds within gp 120 (not shown).
gp41 starts at residue 512 of Env, the first amino acid of the hydrophobic fusion peptide (FP).
Two heptad repeat regions at the N- and C- termini ofgp41 (N-HR and C-HR, respectively) are
linked by a non-helical disulfide-bonded loop. The transmembrane domain (TM) anchors the
Env glycoprotein to the viral membrane, and is followed by a long intraviral portion termed the
cytoplasmic tail (Cyto). The five glycosylation sites in gp41 (at positions 611, 616, 624, 637, and
674) are denoted with a "Y". Amino acids are numbered according to the HXB2 strain (a well-
studied lab-adapted HIV-1 strain) and are written below the schematic.
(B) Model of gp41-mediated fusion. Initial contact with cellular receptors and coreceptors is
made by gp120. This interaction triggers a series of conformational changes within the Env
protein to promote fusion. Specifically, the hydrophobic fusion peptide is released from the
native state and inserts into target cell membrane. Thus, gp41 is anchored between the target cell
(via the FP region) and the virion (via the TM domain), in a prehairpin intermediate. The trimeric
N-HR region is exposed, as are the unstructured C-helices (labeled N and C, respectively). This
structure resolves into a trimer-of-hairpins, in which the C-helices bind the grooves in the central
N-terminal trimer. This transition juxtaposes the viral and cellular membranes. In a poorly
understood process-perhaps involving interaction of multiple trimer-of-hairpin structures, or
mixing of the outer leaflets of each membrane-the two membranes fuse and viral contents are
released into the host cell.
(C) Structure of the HIV-1 trimer of hairpins. gp41 ectodomain fragments from the N- and C-HR
domains assemble in a six-helix bundle structure. At the center are three N-peptides (blue
helices). The grooves between adjacent N-peptides form binding sites for the C-peptides (yellow
helices). These C-helices pack on the outside of the N-terminal trimer in an antiparallel manner.
The location of the FP (blue spheres) and TM (red spheres) regions are indicated. Reprinted with
permission from ref. 14. © Nature Publishing Group, 2003.
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CHAPTER 2
GENERATION OF A STABLE gp41 ECTODOMAIN HYBRID PEPTIDE
FOR USE AS A FUSION INHIBITOR AND A VACCINE CANDIDATE
24
With the following exceptions, all work described in this chapter was performed by TRS. Heng
Chhay did the viral infectivity assays, and Mike Burgess and Ben Sanford chemically synthesized
all peptides. In addition, peptide injections into guinea pigs, as well as neutralization and ELISA
assays, were performed by Michael Citron, Xiaoping Liang, and associates, at Merck Research
Labs in West Point, PA.
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Abstract
We characterized a region of the gp41 N-HR trimer located between the fusion peptide and the
hydrophobic cavity. This 26 residue gp41 fragment, which alone forms aggregates, was
stabilized when fused to a trimeric scaffold peptide, GCN4-pIqI. The hybrid molecule, IQN26,
was helical by circular dichroism, exhibited a cooperative melting curve, and was mostly trimeric
with slight aggregation. IQN26 also inhibited fusion at a low nanomolar concentration. Circular
dichroism studies showed that IQN26 interacts with a C-HR derived peptide, C29. We
hypothesized that IQN26 may function as an inhibitor by sequestering the corresponding C-HR
region of gp4 1. This hypothesis was tested by designing mutations in the N-HR region of IQN26
that abolish its interaction with C29. As expected, the mutant IQN26 molecule no longer
interacted with C29 by circular dichroism and was unable to inhibit fusion.
In order to generate a more potent inhibitor of fusion, the same N26 region of gp41 was
fused to a more stable 'isoleucine zipper' scaffold protein, IZ. This resulting molecule, IZN26,
was indeed more helical, stable, and trimeric than IQN26. Surprisingly however, IZN26 showed
little interaction with C29 and possessed no inhibitory activity up to 10M. The basis for this
lack of inhibitory activity remains unknown.
Finally, to test their efficacy as vaccine candidates, IQN26 and IZN26 were injected into
guinea pigs. Preliminary high throughput screens did not detect any neutralizing activity in the
sera.
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In the late 1980s and early 1990s computer modeling of gp41 suggested that it contained an
amphipathic a-helical region (13, 20). Synthetic peptides containing these sequences were
shown to be helical and capable of inhibiting viral fusion. Secondary structure seemed essential
for this property (36). Subsequent gp41 proteolysis experiments in the mid 1990s revealed the
presence of stable, interacting N-HR and C-HR regions (26, 27). The minimum stable gp41
ectodomain that was identified in these experiments contained 36 residues from the N-HR region
(N36) and 34 residues from the C-HR (C34). Shortly thereafter, in 1997, the first atomic
resolution structures of gp41 were solved (8, 33, 34).
In general, peptides derived from the gp4 1 N- and C-HR regions are thought to inhibit
fusion by preventing gp41 trimer-of-hairpins formation. Interestingly, C-peptides are more
potent fusion inhibitors than are N-peptides. Several lines of evidence support the hypothesis that
these peptides bind the N-HR region of gp4 1 and thus prevent trimer-of-hairpins formation. First,
the antiviral activity of a potent C-peptide can be titrated by addition of exogenous N-peptide
(26). Second, viruses that develop resistance to C-peptides often contain mutations that map to
the N-HR of gp41 (1, 2, 31). Third, C-peptides that are mutated in the N-HR-binding region are
less efficient inhibitors of fusion (7, 35).
Peptides derived from the N-HR region of gp41 are also capable of preventing trimer-of-
hairpins formation. Due to their tendency to aggregate, these peptides are often solubilized and
stabilized by fusion to stable trimeric peptides. There are at least two possible mechanisms for N-
peptide inhibition of fusion. Some reports using stabilized N-peptide cores suggest that they can,
in their trimeric conformation, bind and sequester the C-HR region of gp41 and thus prevent
trimer-of-hairpins formation (15, 24). Alternatively, other evidence indicates that N-peptides
may intercalate into the N-HR region of gp4 1, again disrupting the native trimer-of-hairpins
structure (3).
This study describes a novel N-HR-derived peptide inhibitor of fusion. Unlike other N-
peptides mentioned above, we sought to characterize a region of the N-HR that does not contain a
deep hydrophobic cavity shown to be an essential binding site for several C-HR amino acids (7).
The 26 N-HR residues studied here are flanked by the fusion peptide at the N-terminus and the
hydrophobic pocket at the C-terminus. We aimed to determine whether the cavity is necessary to
maintain folded structure, whether peptides lacking this region contain important determinants of
C-HR binding, and whether these peptides are also potent HIV inhibitors. Using a chimeric
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peptide containing this region fused to a scaffold peptide, we first determined that folding of the
gp41 core is possible in the absence of the pocket. Our hybrid peptide displays an IC50 value in
the low nanomolar range. Further biophysical experiments suggest that this molecule inhibits
fusion by sequestration of the C-HR. Thus, this region of the N-HR does contain important
determinants of C-peptide binding. Finally, in an attempt to generate a novel vaccine candidate,
the serum of guinea pigs immunized with these chimeric peptides was analyzed for a neutralizing
response. None was found.
Materials and methods
Plasmid construction-A 29 residue fragment from the N-HR region of HIV-1 gp41 (residues
539-567 of HIV-1 strain HXB2) was fused to a GCN4-pIqI trimeric scaffold protein; this
molecule, IQN29, was then expressed in E. coli for purification. A longer 51 residue N-HR
fragment (residues 539-590 of HXB2) was initially PCR amplified and cloned into the p-
GCN4pIqIn vector (gift of Mike Milhollen) as a Sphl/BamHl fragment. A stop codon after
residue 567 was introduced by site directed mutagenesis (QuickChange Site-Directed
Mutagenesis, Stratagene). The resulting vector, pGCN4-N29, encodes a 60 amino acid chimeric
peptide containing an N-terminal GCN4-pIqI fragment fused to 29 residues of the N-HR from the
fusion peptide up to and including the first three residues of the hydrophobic cavity. The
sequence of this peptide, IQN29, is: NH2-MRMKQIEKKIEEIEKKQYKIENEIARIKKLI
VQARQLLSGIVQQQNNLLRAIEAQQHLLQ-COOH where the boldface residues are from the
GCN4-pIqI moiety. Additional, tagged versions of IQN29 were also generated. PCR-amplified
IQN29 was subcloned into the pET-16b vector (Novagen), introducing a 6X-histidine tag (HIS-
tag) followed by a Factor Xa protease cleavage site at the N-terminus of IQN29 (yielding a
protein denoted HIS-IQN29). Two maltose-binding protein (MBP) fusion constructs were
generated by subcloning IQN29 into the pMAL-c2G and pMAL-p2G vectors (New England
BioLabs); the pMAL-c2G vector targets the fusion protein to the bacterial cytoplasm while the
pMAL-p2G vector targets it to the periplasmic space. These fusion proteins are called c- or p-
MBP-IQN29 and, in both cases, the MBP portion can be cleaved off with the enzyme genenase.
All constructs were fully sequenced.
Bacterialprotein expression andpurification-Protein expression was induced in late log phase
cultures of BL2 lpLysS E.coli. One liter cultures were harvested after induction with mM IPTG
for 2 to 4 hours at 370C. Numerous attempts were made to purify untagged IQN29 from bacterial
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cultures. Cell pellets were resuspended in 50mM Tris pH 8.5, 15% glycerol with or without 1%
nonidet P-40 and mM EDTA, and sonicated to homogeneity. After two cycles of centrifugation
(35,000 x g, 30 minutes) and sonication, IQN29 remained mostly in the soluble fraction. This
fraction was then purified over anion (DEAE) or cation (CM sepharose) exchange columns. In
both cases, IQN29 was present in the flow-through fraction; we were unable to find conditions in
which IQN29 bound the column resin at several different pHs. Noting that solubility of IQN29
changed dramatically with pH, we performed several dialyses into buffers of varying pHs.
Ammonium sulfate precipitation as well as gel filtration were also employed as tools for further
purification. Using these methods, we were unable to obtain pure fractions of IQN29.
Subsequent purification attempts were made with IQN29 containing either a HIS- or a
MBP tag. Bacterial cultures expressing HIS-IQN29 were lysed as described above, and the
soluble fraction was purified over a Ni-NTA (Qiagen) column. HIS-IQN29 eluted in 10 mM Tris
pH 8 and 50 mM sodium phosphate containing 250 mM imidazole. However, digestion with the
factor Xa protease did not remove the HIS-tag from the N-terminus of IQN29. The pMBP-
IQN29 protein was expressed at very low amounts in the periplasm, so no further purification
attempts were made. Cytosolic cMPB-IQN29, on the other hand, was well expressed in
BL2lpLysS cells. Upon sonication and centrifugation, as described above, the soluble fraction
was separated over an amylose column and cMBP-IQN29 was eluted with 10 mM maltose.
Using the genenase protease, we next attempted to cleave off the N-terminal MBP fragment.
After a 19 hour digest, no protease cleavage was detected. We suspect that the presence of the
strongly helical IQN29 moiety near the factor Xa or genenase cleavage sites may impart some
secondary structure to the cleavage site, making it unrecognizable to the protease.
Since none of the above strategies yielded sufficiently pure, untagged IQN29, we decided
to obtain chemically synthesized peptides for future experiments.
Peptide Synthesis and Purification-All peptide synthesis work was performed by Mike Burgess
and Ben Sanford in the Kim laboratory at MIT. HPLC purification of all peptides was done by
TRS.
Peptides were synthesized on a PE Biosystems 431A peptide synthesizer using standard
Fmoc chemistry (19) and then desalted over a Sephadex G-25 column (Pharmacia). All peptides
are acetylated at the N-terminus and amidated at the C-terminus. Final purification of all peptides
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was performed by reverse-phase HPLC (Waters) over as C 18 preparative column (Vydac) using a
linear gradient of acetonitrile and 0.1% trifluoroacetic acid. Peptides were then lyophilized and
stored under desiccation. Peptide identity was confirmed by matrix-assisted laser desorption
ionization mass spectrometry. The sequences of all synthesized peptides are shown in Figure 1C.
A three amino acid sequence of Tyr-Gly-Gly was added to the N-terminus of N26, IZ, and IZN26
since these three peptides have no chromophoric residues and therefore no way to accurately
determine stock concentrations.
Circular Dichroism-Lyophilized peptides were resuspended in water and concentrations were
determined by absorbance at 280 nm in 6 M guanidine hydrochloride as described (18). Samples
were then diluted to 1 to 40 FtM in PBS (50 mM sodium phosphate pH 7.0, 150 mM sodium
chloride).
All circular dichroism (CD) measurements were taken on an Aviv 62 or 62A DS
spectrometer (Aviv Associates). All wavelength scans were performed with 10 FM samples, and
all thermal denaturation scans with 1 F.M samples, unless otherwise indicated. Theoretical 100%
helicitv was calculated according to the method of Chen et al. (10), and was estimated to be
-35,400 deg cm2 dmol-' for IQN26, IZN26, and mIQN26(3A). Wavelength scans were
performed at 25°C, in a 1 mm cuvette, from 200 to 300 nm with a 5 second averaging time, in
triplicate. Thermal denaturation scans were performed in a 1 cm cuvette in 20C increments
starting at 0°C, with a 1.5 minute equilibration time and a 30 second averaging time.
Peptide mixing experiments were performed using a 1 cm dual compartment mixing
cuvette that contains a barrier between two chambers. In all experiments, 20 ,uM of the N-peptide
(IQN26, IZN26, mIQN26, or N26) was mixed with 22 ,uM of C29. The 'before mixing' scans
were obtained when the contents of the chambers remained separate. Parafilm was then placed
over the cuvette opening and the cuvette was inverted several times in order to thoroughly mix
the contents. After several minutes to hours, the mixed sample was then scanned and recorded as
the 'after mixing' sample. The parameters for these wavelength scans are the same as those
described above.
Sedimentation Equilibrium-All peptide samples were centrifuged at 250C in a Beckman XL-A
analytical ultracentrifuge (Beckman) with a An-60 Ti rotor. Peptides were dialyzed overnight
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against PBS, diluted to three concentrations ranging from 20 to 80 p.M, and centrifuged at rotor
speeds of 15, 20, and 25 krpm. Data were collected at 230, 235, and 280 nm.
HIVlnfectivityAssay-TRS provided peptide dilutions, and Heng Chhay (Kim Laboratory, MIT)
performed all viral infectivity assays. Replication-incompetent virus was made as described (9).
Specifically, 293T cells were cotransfected with a packaging vector containing all viral structural
genes except Env and Nef (Nef was replaced with the luciferase gene), and an expression vector
encoding HXB2 gpl60. This virus was used to infect HOS-CD4/fusin cells (N. Landau, NIH
AIDS Reagent Program) in the presence of inhibitory peptides. Cells were lysed two days post-
infection and luciferase activity was measured in a Wallac AutoLumat luminometer. The peptide
concentration that results in 50% inhibition of viral infection (IC50) was calculated by fitting the
data to a Langmuir equation [y=k/(1+[peptide]/IC50)] where y is the luciferase activity and k is a
scaling constant.
Cell-cell Fusion Assa--Similar to the viral infectivity assay, the ability of gp4 1-derived peptides
to inhibit cell-cell fusion was determined in a syncytia assay. Chinese hamster ovary (CHO) cells
expressing gpl60, Tat, and Rev (23) and HeLa-LTR--gal cells expressing CD4 (M. Emerman,
NIH AIDS Reagent Program) were used. Fusion of these cell types to form syncytia
(multinucleate cells) allows Tat-mediated expression of P-gal from the viral LTR promoter.
Approximately 2x104 CHO cells and 4x104 HeLa cells were mixed in 8-well slides. After 18-20
hours of coculture, cells were fixed with 0.5% glutaraldehyde and stained with 5-bromo-4-chloro-
3-indolyl-p-D-galactoside (X-gal). Syncytia containing three or more nuclei were counted under
bright field microscopy.
Animal Immunizations-IQN26 and IZN26 were sent to Merck Research Labs for injection into
guinea pigs and characterization of the sera. This work was done by Michael Citron, Xiaoping
Liang, and colleagues. Female guinea pigs were injected intramuscularly three times (t = 0, 4, 8
weeks), with 100 Rg peptide and 40 gg QS21 adjuvant per injection. Serum was sampled at
weeks 3, 8, and 12, and tested in ELISA and neutralization assays.
Results and discussion
These studies aim to characterize a 26 amino acid N-HR segment of gp41, which starts five
residues after the fusion peptide (12) and spans virtually the entire region between the fusion
31
peptide and the hydrophobic cavity (the sequence of this region is shown in Figure 1). This
fragment is denoted N26, and is composed ofgp41 residues 539-564. The N26 region has been
crystallized in the context of a longer N-helix segment (34) and is shown to be helical and
trimeric. Circular dichroism analysis of the N26 peptide alone, however, shows that it lacks
secondary structure (Table 1 and Figure 2A) and therefore does not properly represent the N-HR
coiled coil observed in gp41 x-ray structures. Furthermore, unlike many N- and C-HR-derived
peptides, N26 does not inhibit fusion (Table 1).
Most isolated N-HR peptides (those in the literature contain the hydrophobic cavity)
exhibit little helicity and tend to aggregate (15, 26, 27). This property can be overcome by
mixing N-HR peptides with their C-peptide binding partners; the complex often adopts a more
helical and stable conformation, as seen with both HIV and SIV (4, 26). Alternatively, N-
peptides can be fused to heterologous peptides that themselves form stable trimers; these
scaffolds impart structural stability to the N-HR region (15, 16, 24, 34). Mixing N26 with its C
peptide binding partner failed to increase the helicity of either N26 or the C peptide (Figure 2A).
This lack of secondary structure, even in the presence of its binding partner, suggests that N26
alone may be too aggregated to form complexes, or that this region of the N-HR requires
neighboring residues in order to make the necessary C-peptide contacts. Thus, we decided to
utilize the second approach in order to better study this region in the context of its native
conformation.
To improve the properties of the N-HR peptide, we fused N26 to GCN4-pIqI, a stable
and trimeric peptide (15-17); the resulting chimeric molecule is termed IQN26. GCN4-pIqI is
derived from the GCN4 coiled-coil model, in which the oligomerization state of coiled coils has
been changed by mutation of residues buried at the helical interface (17, 22, 30). Figure 1 shows
the arrangement of gp41 N-HR and C-HR residues on a helical wheel, as well as the sequence of
IQN26 and other chimeric peptides used in this study.
In contrast to the N26 peptide, circular dichroism experiments reveal that IQN26 forms a
stable, helical structure and has a melting temperature of 700C (Table 1). Analytical
ultracentrifugation experiments suggest that the peptide is a slightly aggregated trimer in solution.
The overall stable secondary structure of IQN26 indicates that the cavity-containing portion of
gp41 is not required for N-HR folding.
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Next, we performed cell-cell fusion assays and viral infectivity assays to determine
whether IQN26 is capable of inhibiting fusion. In these assays, N26 alone fails to demonstrate
any inhibition potential (Table 1), most likely because of its aggregated or non-native structure.
IQN26, on the other hand, is indeed a potent inhibitor, exhibiting IC50 values of 70 nM and 40 nM
in each assay, respectively (Table 1). Similar chimeric molecules containing the cavity region
also inhibit fusion (in the -200 nM IC50 range) while the GCN4-pIqI moiety alone has no
inhibitory activity (15).
To distinguish between two possible mechanisms for IQN26 inhibition-sequestration of
the C-HR or intercalation into the N-HR-we assessed its ability to bind to a C-peptide,
mimicking the intramolecular gp41 interaction. Since most C peptides studied to date were
designed to interact with the pocket-containing N-helix region, we used the SIV and HIV solution
and crystal structures (5, 6, 8, 26, 28, 34) to align N26 with the C-HR region. The resulting C-
peptide, C29, closely overlaps the N26 region when visualized in the context of the six-helix
bundle, and alone lacks secondary structure (Figure 1 and Table 1). We used a circular dichroism
peptide mixing assay to measure the interaction between the N- and C-HR peptides. CD scans
were obtained before and after mixing 22 gM IQN26 and 20 gM C29 solutions in a dual chamber
mixing cuvette. IQN26 and C29 appear to interact, as evidenced by a considerable increase in
helical signal upon mixing (Figure 2B). In contrast, both N26 and C29 remain unstructured
during mixing (Figure 2A), lending further support to the hypothesis that N26 is primarily
aggregated in PBS. These initial results suggest that IQN26 may inhibit by binding and
sequestering the C-HR region of gp41; however, these studies alone do not rule out the
intercalation model.
To further test the mechanism of IQN26 inhibition, we made mutations in IQN26 that
were designed to abolish C-peptide interaction. Residues Leu-544, Gln-551, and Gln-563 at the e
and g positions of N26 (Figure 1, B and C) were chosen based on their nearest-neighbor contacts
(using the Contact and Insight II software programs ((1 1) and Accelrys, San Diego)) and the
reported crystal structures. A mutant molecule, termed mIQN26(3A), contained mutations of the
above three residues to alanine. Biophysical experiments confirm that mIQN26(3A) has
properties similar to the parent IQN26 molecule: 67% helicity and a 700C thermal denaturation
midpoint. In syncytia assays, mIQN26(3A) shows no fusion inhibition at concentrations up to 10
!xM (Table 1). As expected based on its design, mIQN26(3A) does not interact with C29 by CD
mixing (Figure 2C), as seen by the overlapping spectra before and after mixing. These results
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show that abolishing interaction with the C-peptide debilitates N-peptide inhibitory activity and
strongly suggest that IQN26 inhibits fusion by sequestering the C-HR region.
In addition to GCN4-pIqI, we used a designed trimeric peptide (isoleucine zipper or IZ)
as a scaffold for N26. The IZ scaffold used here is modified from a synthetic, designed coiled
coil that contains charged residues on the outer face (at the e and g positions, see Figure 1 for
description), thus allowing electrostatic interactions between adjacent helices (32). It has been
previously used to stabilize cavity-containing N-HR peptides (15). IZN26 exhibits an even more
stable structure than IQN26, with a melting temperature of 82°C. Furthermore, IZN26 does not
display any signs of aggregation up to 60 gM (Table 1). Based on this increased stability, we
hypothesized that IZN26 would interact more strongly with C29 and thus be a more potent fusion
inhibitor. Surprisingly, this hypothesis proved incorrect. IZN26 shows little interaction with
C29; unlike the 41 mdeg increase in helical signal upon IQN26 and C29 mixing, mixing IZN26
and C29 increases the helicity by only 15 mdeg (Figure 2, B and D). Since the GCN4-pIqI
portion does not inhibit fusion (15), it is unlikely to interact with C29; however, this control was
not performed in these CD mixing studies. Furthermore, IZN26 did not inhibit cell-cell fusion up
to the highest concentration tested (10 FM) (similar studies with the IZ portion indicate that it
alone does not inhibit fusion (15)).
The reason for the difference between IQN26 and IZN26 in terms of C-peptide binding
and inhibitory properties remains unclear. Perhaps the N26 region in a tightly-associated coiled
coil (i.e. IZN26) is unable to efficiently interact with the C-helix. IQN26, in a more dissociated
form, may still be capable of this interaction. While this explanation could be valid for the N26
region, other work with cavity-containing N-HR peptides has shown a different result.
Simultaneous experiments were performed in the Kim lab with the N-HR hydrophobic cavity
residues fused to GCN4-pIqI (IQN17) or IZ (IZN17) (15). These studies show that stability is
correlated to inhibitory activity; IZN 17 is the more stable of the two molecules, and possesses a
tenfold greater inhibitory potency. Furthermore, since IZN17 is a potent inhibitor, it is unlikely
that the highly charged IZ moiety in IZN26 interacts unfavorably with gp4 1. It is unclear why
this correlation does not hold true for non-cavity N-HR peptides. Cumulatively, these results
suggest that folding and stability are not the only determinants of inhibitory potential.
It is indeed possible that in the pre-hairpin intermediate, the cavity region is a tightly-
associated trimer that then splays apart toward the fusion peptide. Synthetic fusion peptides have
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been studied in isolation, a difficult task given their extremely low solubility. Evidence indicates
that the HA fusion peptide inserts obliquely into the outer leaflet of the target membrane and
consists of two ca-helices that are interrupted by a kinked region (14). While the structure of a
trimeric fusion peptide molecule is unknown, it is possible that each monomeric fusion peptide,
and perhaps some neighboring N-HR residues, may splay apart and insert at the same oblique
angle into the target membrane. The resulting difference in structural properties could lead to a
cavity-containing peptide being a better inhibitor as a stable trimer, and a region closer to the
fusion peptide being more potent in a slightly dissociated form.
The CD mixing experiments contain some caveats, leading to the possibility that this
method does not accurately measure the level of N- and C-peptide interaction. First, the increase
in helicity upon IQN26 and C29 mixing could be a result of both the C-peptide and IQN26
adopting a more helical conformation. Since IZN26 is already more helical and stable than
IQN26, perhaps there is no concomitant increase in IZN26 helicity when it is mixed with C29.
By extension, the difference in C29 interaction between the IQN26 and mIQN26(3A) (Figure 2, B
and C) may be more accurately reflected in the CD mixing assay since both N-HR chimeric
peptides are equally stable and helical at the outset. A second, minor caveat is that we have not
ruled out the possibility that the GCN4-pIqI moiety of IQN26, and not the N-HR region or the IZ
scaffold, is interacting with C29. This is highly unlikely since the GCN4-pIqI moiety would then
presumably demonstrate some inhibitory activity.
Upon closer biophysical examination of the chimeric N-peptides, we determined that all
three N-HR peptides in this study display a concentration-dependent helical signal (Figure 3). As
they are diluted from 40 or 10 ,uM to 1 xM, these peptides lose helical signal. Our model of
IQN26 inhibition suggests that it interacts with C29 as a helical trimer and that this interaction is
correlated with its inhibitory potency. Other studies also suggest that N-peptides inhibit in their
helical, trimeric conformation (15, 24, 25) and their potency is often improved with greater
helicity. Due to the limits of detection in CD, we cannot perform biophysical studies at low
nanomolar (IC50) concentrations. However, the CD dilution experiments indicate that the helical
N-trimers dissociate at low micromolar concentrations, leading to the possibility that at low
nanomolar (ICSo range) concentrations these peptides are in fact monomeric. In addition, these
results suggest that dilution of IQN26 from 22 .M to 11 ,uM in the C29 mixing experiments may
slightly decrease IQN26 helicity and may be another potential explanation why the post-mixing
spectrum is not as helical as IQN26 before mixing. Future experiments to measure the interaction
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between chimeric N-HR peptides and C29 would include thermal denaturation and analytical
ultracentrifugation of peptide complexes.
Finally, the trimeric N26 region of gp4 1 is thought to be exposed as a transient
intermediate in the fusion pathway. While it is possible that antibodies directed against this
region may prevent gp41 trimer-of-hairpins formation, no such antibody has yet been identified.
This could be due to the transient nature of the prehairpin intermediate, or to the possibility that
binding of antibodies to this region may be sterically hindered (21).
In order to examine their potential as vaccine candidates, our chimeric N-HR peptides
were used as immunogens to elicit an antibody response. Since both peptides were well-
characterized biophysically, and the structure of the N-HR region in the prehairpin intermediate is
unknown, both the weaker (IQN26) and the stronger (IZN26) N-HR trimers were used for these
experiments. The peptides were injected intramuscularly into guinea pigs and the sera were
analyzed using ELISA and neutralization assays (Merck Research Labs). Neither peptide had
neutralizing activity in these preliminary screens, and therefore no further immunization studies
were conducted.
A detailed understanding of gp4 conformational changes, by biophysical, mutagenic,
and crystallographic analysis, will aid in the design of peptide immunogens and inhibitors. .For
example, if future work shows that the N26 region is indeed splayed apart, immunogens can be
designed to weakly trimerize these residues. Perhaps a scaffold that is more weakly trimeric than
GCN4-pIql may be tried.
An important future experiment should switch the location of the scaffold in the chimeric
peptide. The N-terminus of N26 is close to the fusion peptide and the target membrane, whereas
the C-terminus is adjacent to the strongly trimeric hydrophobic cavity. In the present study, the
trimeric IQ or IZ moiety is anchored to the N-terminus of N26, adjacent to the target membrane.
A molecule with IQ or IZ at the C-terminus, essentially replacing the trimeric hydrophobic cavity,
may serve as a better gp4 1 mimic. Additionally, design of such a molecule would reduce the
chance of the scaffold interacting unfavorably with the target phospholipid bilayer.
gp41 is highly immunogenic in HIV infected patients, and sera from these patients react
with peptides that mimic all regions of the protein (such as the fusion peptide, N-HR, C-HR, and
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the six-helix bundle structure) (29). However, it is unclear when reactive antibodies actually bind
the gp41 protein in vivo. They could bind gp41 when Env is in its native conformation, before
fusion has been triggered. Alternatively, antibody binding could occur during the fusion process
when intermediate structures are transiently exposed, or after fusion is complete and the Env
protein lies exposed on the surface of the newly infected cell. Finally, antibody binding could
also be induced during premature Env triggering when there is no target cell present. The main
questions in vaccine design that remain to be answered are (1) Can antibodies access epitopes that
are exposed between the virus and target cell (i.e., in the prehairpin intermediate), or are they
sterically inhibited? (2) What are the key neutralizing epitopes? (3) How specific does the
antibody-epitope interaction have to be (i.e., can an antibody bind anywhere on the N-HR or does
it have to bind specifically to the cavity, for example, in order to prevent N-C interaction)? and
(4) How high does the neutralizing titer in the sera have to be in order to efficiently prevent
infection? These are areas of intense investigation, both in the basic science realm and in clinical
trials. Chapter 4 further explores advances in vaccine research and other approaches being taken
to prevent viral entry.
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Table 1: Biophysical properties and inhibitory activity of N26 chimeric
CD Wavelength Scan' Thennrmal Denaturationb Analytical Ultracentrifugation b
0222 % helicity Tm Properties Concentration MWobscalCc Residuals d
(°c)
peptides
Fusion Inhibition be
Cell-cell Virus-cell
IC50 IC50
69%
ND
700C cooperative,
reversible
67% 70°C cooperative,
reversible
ND -
91% 820C cooperative,
reversible
ND
20 gM
50 jiM
70 gM
ND
ND
20 oM
40 M
60 M
3.25
3.54
3.65
2.87
3.10
3.02
slight aggregation
slight aggregation
slight aggregation
random
random
random
> 10 uM
70 nM
> 10 pM
40 nM
> 10 M ND
>0.63 pM
> 10 giM
ND
ND
' The CD signal at 222 nmn (022) and the percent helicity are reported for 10 ugM peptide solutions in PBS. The theoretical 100% helicity value for IQN26,
mlQN26(3A), and IZN26 is -35,400 deg cm2 dmol'l.
b ND: experiment not done.
' Sedimentation equilibrium results are shown as the ratio of observed molecular weight (Mb,) to calculated molecular weight for a monomer (c,). An ideal
trimer has an M oblMl,ac ratio of 3.00.
d For IQN26, some non-random residuals were observed for all three concentrations ofpeptide. In those cases, the upward curvature of the residuals indicated
slight aggregation of the peptide.
' Syncytia assays and viral infectivity assays were used to assess the ability of N-HR and C-HR peptides to inhibit cell-cell and virus-cell fusion. The IC,0 values
reported are from a single representative assay done in duplicate.
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Peptide
N26
IQN26
mIQN26(3A)
C29
IZN26
unstructured
-24,500
-23,700
unstructured
-32,200
I
(deg c 2dmol- ')
Figure 1. Helical wheel alignment of gp41 and peptide sequences.
(A) In the fusion-active structure of HIV-1 gp41, the N-terminal helices form a trimeric coiled
coil. They contain a characteristic heptad repeat motif, in which the first (denoted the a position)
and fourth (d position) residues of each seven-residue repeat interact in the interior of the coiled
coil. Residues at these positions are generally, although not always, hydrophobic. In contrast,
residues on the outer face of the coiled coil are often polar. In the gp41 core, C-terminal helices
pack into the grooves between adjacent N-helices in an antiparallel manner. N-HR e and g
position amino acids form contacts with these C-helices. This pattern is more clearly viewed
when arranged on a helical wheel, as shown here.
(B) The sequence of the N26 and C29 residues are shown on a helical wheel diagram. Shaded
dots indicate the three residues mutated to alanine in mIQN26(3A).
(C) The sequences of all chemically synthesized peptides are shown. All peptides are acetylated
at the amino terminus and amidated at the carboxy terminus.
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A
C29
B
*Q563
L556
V549
D r.1
-
L545 (
Q552
1559
A541 .L,544
1548 .Q551
L555 A558
Q562
S668
L661
D664 E654
E657 E647
..... 
I
1646
Q653
L660
A I- .'
1642 L645
S649 Q652
N656 E659
1.663 W666
Peptide
N26
IQ
IQN26
mIQN26(3A)
IZ
IZN26
C29
Sequence
Ac -YGGVQARQLL SGIVQQQNNLLRAIEAQQH-NH2
Ac-RMKQIEDKIEEIESKQYKIENEIARIKKLI-NH2
Ac-RMKQIEDKIEEIESKQYKIENEIARIKKLIVQARQLLSGIVQQQNNLLRAIEAQQH-NH2
Ac-RMKQIEDKLEEIESKQYKIENEIARIKKLIVQARQALSGIVQAQNNLLRAIEAQAH-NH2
Ac-YGGIKKEIEAIKKEQEAIKKKIEAIEKEI-NH2
Ac-YGGIKKEIEAIKKEQEAIKKKIEAEKEIVQARQLLSGIVQQQNNLLRAIEAQQH-NH 2
Ac-SLIHSLIEESQNQQEKNEQELLELDKWAS-NH2
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E560
N553
S546
V539
H564
R557
Q550
Q543
) Q540
G547
;z ;1INJJI
A561
K665
Q658
651
544
L641
E648
K655
E662
C
C29O I2
Figure 2. Interaction of chimeric N-HR peptides with C29.
Circular dichroism wavelength scans of peptide solutions in PBS were obtained using a dual
compartment mixing chamber. Initial scans of the N-helix peptides (IQN26, IZN26,
mIQN26(3A), or N26) were performed with a 20 M peptide sample in one chamber and PBS
buffer in the other. Similar initial scans were performed with 22 F±M C29 in one chamber and
buffer in the other. A 'before mix' spectra was obtained with 20 FM N-peptide in one chamber
and 22 FtM C29 in the other. The cuvette was inverted to mix the samples, and an 'after mix'
scan was then performed. The wavelength scans for N26 (A), IQN26 (B), mIQN26(3A) (C), and
IZN26 (D) mixed with C29 are shown.
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Figure 3. Concentration-dependent secondary structure of chimeric N-HR
peptides.
N-HR chimeric peptides were serially diluted and assayed for helicity by circular dichroism. For
IQN26 (A) and mIQN26(3A) (B), samples were diluted in a mixing cell. For IZN26 (C), serial
dilutions were scanned in a 1 cm cuvette.
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CHAPTER 3
THE FUSION ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)
GP41 DEPENDS ON INTERHELICAL INTERACTIONS
Chapter 3 has been published as:
Tara R. Suntoke and David C. Chan,
'"The Fusion Activity of HIV- 1 gp4 1 Depends on Interhelical Interactions."
Journal of Biological Chemistry 280, 19852-19857 (2005).
(© 2005 American Society for Biochemistry and Molecular Biology.
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Abstract
Infection by human immunodeficiency virus type I (HIV-1) requires the fusogenic activity of
gp41, the transmembrane subunit of the viral envelope protein. Crystallographic studies have
revealed that fusion-active gp41 is a "trimer-of-hairpins," in which three central N-terminal
helices form a trimeric coiled coil surrounded by three antiparallel C-terminal helices. This
structure is stabilized primarily by hydrophobic, interhelical interactions, and several critical
contacts are made between residues that form a deep cavity in the N-terminal trimer and the C-
helix residues that pack into this cavity. In addition, the trimer-of-hairpins structure has an
extensive network of hydrogen bonds within a conserved glutamine-rich layer of poorly
understood function. Formation of the trimer-of-hairpins structure is thought to directly force the
viral and target membranes together, resulting in membrane fusion and viral entry. We test this
hypothesis by constructing four series of gp41 mutants with disrupted interactions between the N-
and C-helices. Notably, in the three series containing mutations within the cavity, gp41 activity
correlates well with the stability of the N-C interhelical interaction. In contrast, a fourth series of
mutants involving the glutamine layer residue Gln-653 show fusion defects even though the
stability of the hairpin is close to wild-type. These results provide evidence that gp41 hairpin
stability is critical for mediating fusion and suggest a novel role for the glutamine layer in gp4 1
function.
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Structural analyses of the transmembrane subunits of several viral envelope proteins (Env)' have
provided much insight into the mechanism of Env-mediated membrane fusion. Remarkably, the
putative fusion-active structures of these proteins from retroviruses (e.g. HIV, SIV, MoMLV),
orthomyxoviruses (influenza), paramyxoviruses (SV5, HRSV), filoviruses (Ebola), and
coronaviruses (SARS-CoV) (1,2) all reveal the same six-helix bundle conformation. This six-
helix structure can also be described as a trimer-of-hairpins, in which each hairpin consists of an
N-terminal helix (N-helix) packed against an antiparallel C-terminal helix (C-helix). Three
central N-helices form a coiled-coil surface with three prominent hydrophobic grooves that each
allow C-helix binding (3-6). Thus, the trimer-of-hairpins structure is largely stabilized by
hydrophobic packing between the three internal N-helices and between the N- and C-helices
(Figure 1, A and B). This fusion-active configuration juxtaposes the amino terminus of gp41,
which contains a fusion peptide inserted into the target cell membrane, with the carboxyl
terminus, which contains the transmembrane anchor in the viral membrane. The current model
for membrane fusion proposes that formation of the hairpin structure provides the energy
necessary for viral and cellular membrane apposition, leading to membrane fusion (1,3,6).
There are two prominent features of the trimer-of-hairpins structure in HIV and SIV
gp41. First, three symmetric hydrophobic cavities on the surface of the N-helix coiled coil each
forms a docking site for three residues from a C-helix. Notably, small peptides or synthetic
molecules targeted to these cavities prevent trimer-of-hairpins formation and inhibit fusion (7,8);
the efficacy of these molecules underscores the critical role of interhelical interactions within the
cavity in gp41 function. Second, a planar cluster of conserved glutamine and asparagine residues,
from both the N- and C-helices, form a hydrogen-bonded layer within the six-helix bundle
(5,6,9). Though a novel structural feature, the function of this 'glutamine layer' remains unclear
(6,9); indeed, none of the reported mutations in this region reduce gp41 activity. In fact, such
substitutions can increase gp41 core stability (10-12) and, in the unusual case of a Gin-652 to
leucine mutation (Q652L), appear to increase fusogenicity (13).
Several mutational and biophysical analyses of gp41 support the hypothesis that hairpin
formation provides the driving force for membrane fusion. For example, the N-helix residues
Leu-565, Leu-568, and Val-570, located on the cavity surface, form hydrophobic contacts with C-
helices as determined by x-ray crystallography. Alanine mutations at these positions decrease
six-helix bundle stability and reduce envelope-mediated fusion (12-16). These mutations are
notable because they likely represent a specific defect in the fusion pathway, unlike some N- and
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C-helix mutants that fail to correctly process the gpl60 precursor into gp120 (the receptor binding
subunit) and gp41 (11,12,16). Although these studies support a role for hairpin formation in
membrane fusion, a systematic analysis of the correlation between hairpin stability and gp41
activity would provide a more rigorous test of the model.
In this study we seek to identify the energetic contribution of the N-C helical interaction
to the fusion reaction. We made a series of substitutions at each of four positions in the N-C
helical interface. We report that for mutations within the N-helix cavity, the fusion activity of
gp41 depends on the stability of the N-C interface. In contrast, for the series of substitutions in
the glutamine layer, we find that gp41 activity is abolished even in the presence of stable N-C
interactions, thereby providing evidence for an important role for the glutamine layer in gp41-
mediated fusion.
Materials and methods
Plasmid Construction and Mutagenesis-Env mutations were made using QuickChange site-
directed mutagenesis (Stratagene) of pBS-SKII containing HXB2 gp160 (pBS-SKII-gp 160), and
verified by DNA sequencing. For expression in 293T cells, all mutations were subcloned into
pcDNA 1.1/Amp (Invitrogen). For generation of stable cell lines, the mutations were subcloned
into the pB-IRES-CD2 retroviral vector (gift from Jonathan Bogan, Whitehead Institute,
Cambridge MA).
For expression of recombinant proteins, mutations were cloned into the pAED4 vector
(4). Mutant N34 and wild-type C28 fragments were PCR amplified from pBS-SKII-gp160 using
the following primers: N34for (5' GCAATTCCATATGTCTGGTATAGTGCAGCAG) and
L6N34rev (5' ACCGCGACCACCGCTTCTGCTTGGAGCTGCTTG) for the N34 fragment,
and L6C28for (5' GGTGGTCGCGGTGGTITGGATGGAGTGGGACAGAG) and C28-HISrev
(5' GGAATICCTAGTGATGATGATGATGATGCTlITCTGCTGGTITGC) for the C28
fragment. These primers introduce a six residue linker (Ser Gly Gly Arg Gly Gly) between N34
and C28, and a 6X-histidine tag (HIS-tag) 3' of C28. For mutant C28 fragments, C28-HISrev
primers encoding the mutations were used. The N and C fragments were joined by overlap PCR
with primers N34for and C28-HISrev, and subcloned into pAED4.
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Protein Expression and Purification-Bacterial cultures expressing N34(L6)C28-HIS variants
were induced with 1 mM IPTG for 3 to 4 hours. Cell pellets were resuspended in lysis buffer (50
mM Tris (pH 8), 15% glycerol, and 300 mM NaCI) containing 10 9tM MgCl2, 1 gM MnC12, and
100 gg/mL DNase I, lysed by sonication, and centrifuged (27,000 x g for 30 minutes) to separate
the soluble and inclusion body fractions. The pellet was washed again in lysis buffer and
supernatants from both washes were pooled. With the exception of the glycine mutants, all
peptides were present in the soluble fraction and were affinity-purified using nickel-
nitrilotriacetate (Ni-NTA) (Qiagen, Inc.). For the glycine mutants, inclusion body pellets were
solubilized in lysis buffer containing 6 M guanidine-HCI before purification using Ni-NTA
beads. Peptide-containing fractions were dialyzed into 5% acetic acid, purified to >95% purity
over a preparative C5 column by reverse-phase HPLC, and lyophilized.
Circular Dichroism Spectroscopy-Lyophilized peptide was dissolved in water, and
concentrations were determined by absorbance at 280 nm in 6 M guanidine-HCl (17). Peptides
were then diluted to 10 F±M in PBS (50 mM sodium phosphate, 150 mM sodium chloride (pH 7)).
Circular dichroism (CD) spectra were obtained on an AVIV 62DS CD spectrometer. To
determine helical content, a value of -33,000 deg cm2 dmol-' was used for theoretical 100%
helicity (12). Thermal denaturation scans were performed on 10 ytM peptide samples in PBS.
The midpoint of the thermal unfolding transition (Tm) was calculated as the maximum value of
the first derivative of the molar ellipticity [0] at 222 nm with respect to temperature. Consistent
with previous reports for N34(L6)C28 (10,11), thermal denaturation of these recombinant
peptides was cooperative but not reversible.
Sedimentation Equilibrium-All measurements were recorded on a Beckman XL-I analytical
ultracentrifuge with a Ti-60a rotor. Wild-type N34(L6)C28-HIS was dialyzed overnight in PBS
or sodium acetate buffer (50 mM sodium acetate. 150 mM NaCI (pH 5.5)), and diluted to 5, 10,
and 30 M. Samples dialyzed in PBS formed some precipitate, while samples in sodium acetate
remained fully soluble. Data were collected at 20°C, with rotor speeds of 20, 30, and 42 krpm
and wavelengths of 229 and 280 nm. Data sets were fitted simultaneously with WinNONLIN
(version 1.06) (18). No systematic residuals were observed, and both samples fit well to a single
species model.
Because wild-type N34(L6)C28-HIS formed stable trimers in both buffers and remained
fully soluble after overnight dialysis at low pH, mutant peptides were analyzed in the sodium
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acetate buffer. All N34(L6)C28-HIS variants except L565G fit best to a single species model,
showed no systematic residuals, and had molecular weights within 10% of those calculated for an
ideal trimer. The L565G peptide was predominantly trimeric in solution, but the data fit slightly
better as a monomer-trimer equilibrium containing 80% trimers.
Envelope Glycoprotein Expression and Western Blot Analysis-Mutant envelope glycoproteins
were expressed in 293T cells by transient transfection for expression analysis and cell-cell fusion
assays. 293T cells were plated in gelatin-coated 12-well plates. At -30 to 50% confluency, cells
were transfected with 800 ng pcDNA-gpl60 expressing mutant gpl60 and 400 ng pnGFP (a
plasmid expressing nuclear GFP) using Lipofectamine 2000 (Invitrogen). Transfection efficiency
was assessed by GFP fluorescence, and was similar for all mutants (-30-50%).
Envelope expression was measured by Western blot analysis. gp41 and gp160 from cell
lysates were analyzed with an anti-gp41 monoclonal antibody, Chessie 8 (National Institutes of
Health AIDS Research and Reference Reagent Program). Shed gpl20 was immunoprecipitated
from the culture supernatant using an anti-gp120 polyclonal antibody (gift of Peter Kim, Merck
Research Laboratories, West Point PA), and protein-A Sepharose beads (Sigma). To determine
cell surface expression levels of Env, transfected cells were washed with cold PBS (pH 8.0) and
biotinylated using 5 mM Sulfo-NHS-LC-Biotin (Pierce) in PBS for 30 minutes at 4°C. After
washing with PBS containing 100 mM glycine to remove excess biotin, cells were lysed in PBS
containing 1% NP-40 (Sigma). Biotinylated surface proteins were precipitated using
immobilized NeutrAvidin (Pierce) and separated by SDS-PAGE.
Stable cell lines expressing the alanine mutants were made using retroviral transduction
of NIH3T3 cells. To generate retrovirus, 293T cells were plated on gelatin-coated 60 mm plates,
and transfected with pBI-CD2-gp60 encoding mutant gpl60 and a MoMLV packaging vector,
pCLeco (gift from C. Lois, Massachusetts Institute of Technology). A 1:2 dilution of viral
supernatant was used to infect NIH3T3 cells in the presence of 4 Rg/ml polybrene. After several
passages, the infected NIH3T3 cell lines were used for dye transfer assays.
Cell-Cell Fusion Assay--Forty-eight hours after transient transfection, 293T cell monolayers
were resuspended and counted. A mixture of 4 x 104 envelope-expressing 293T cells and 4 x 104
target cells, 3T3-T4-CXCR4 (National Institutes of Health AIDS Research and Reference
Reagent Program), was plated in duplicate into gelatin-coated 8-well slides and incubated for 21
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hours at 37°C. After fixation and hematoxylin staining, the number of syncytia per well was
counted under phase microscopy. Cells containing three or more nuclei were scored as syncytia.
Dye Transfer Fusion Assay-3T3 cells stably expressing gp41 mutations were plated at a density
of 1 x 106 cells per 60 mm dish. Eight hours later, cell monolayers were incubated with 420 nM
calcein AM (Molecular Probes) in PBS for 10 minutes at 37°C and gently washed twice with PBS
before addition of labeled target cells. Target cells, 3T3-T4-CXCR4, were labeled with the lipid
dye octadecyl rhodamine B (R18) (Molecular Probes). 2 x 106 target cells were washed in PBS,
incubated in PBS containing 2 M R18 for 15 minutes at room temperature in the dark, and
washed twice in PBS before resuspending in growth media. Approximately 4 x 105 target cells
were added to envelope-expressing monolayers, and dishes were immediately incubated at 370C.
Cells were examined for dye transfer every 20 to 30 minutes by counting the number of co-
labeled cells in five separate fields at 200X magnification.
Results
Design offour allelic series-Residues Leu-565, Leu-568, and Val-570 are located on the surface
of the N-terminal coiled coil within a large cavity and interact with the internal face of the C-
helix (Figure 1, A and B). In previous studies, mutation of these residues to alanine reduced
fusion but did not affect gp 160 processing or gp 120-gp41 association (12-15), suggesting a
specific defect in the fusion pathway. In order to obtain a range of gp4l core stabilities, each
position was mutated to glycine, alanine, and phenylalanine. We chose glycine for its helix
destabilizing properties (19), alanine for its reduced hydrophobic bulk, and phenylalanine for its
increased bulk over the native leucine or valine residue.
The polar contacts within the glutamine layer were disrupted by mutagenesis of Gln-653
(Figure 1C). This residue is buried in the interhelical interface and forms hydrogen bonds with
neighboring helices in the core crystal structure (6,20). Furthermore, it is highly conserved; only
two out of 630 viruses in the Los Alamos HIV Sequence Database show mutations at this position
(http://www.hiv.lanl.gov). The Q653A and Q653L substitutions were designed to abolish polar
contacts with neighboring glutamine residues, whereas the Q653E substitution retains bulk and
polarity.
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Biophysical analysis of recombinant gp41 core structures-We used a recombinant peptide
model to measure the biophysical properties of mutant gp41 cores. This gp41 core peptide,
termed N34(L6)C28-HIS, contains N- and C- terminal helices that are joined by a six residue
linker (Figure 1A). It is similar to the previously described N34(L6)C28 peptide (21), but
contains a C-terminal HIS-tag to facilitate purification. Circular dichroism indicates that the
molecule is >90% helical and thermostable, with a thermal denaturation midpoint (Tm) of 74°C.
In addition, it forms a discretely trimeric species as determined by sedimentation equilibrium
(Figure 2 and Table 1). When compared with published data for N34(L6)C28, N34(L6)C28-HIS
has a 40C higher melting temperature. We speculate that addition of the C-terminal tag promotes
stability by attenuating the helix dipole moment or by reducing fraying of the helical ends
(19,22).
For the three mutant series involving the N-helix, biophysical analysis indicated that we
successfully generated a wide range of stabilities in the gp41 core (Table 1). In each position, all
mutants are less stable than wild-type, with the relative order Gly < Ala < Phe < WT. At position
568, the phenylalanine mutant (Tm of 61°C) is only slightly more stable than the alanine mutant
(Tm of 60°C). The low stability of the L568F variant may be caused by local distortion to
accommodate the large aromatic ring. All mutants are highly helical and, with the exception of
L565G (see Materials), the least thermostable variant in this study, all form clean trimers as
evidenced by sedimentation equilibrium analysis (Table 1).
Interestingly, mutations at Gln-653 do not appreciably destabilize the six-helix bundle
structure. The Q653A, Q653L, and Q653E mutants have Tm values close to wild-type, and form
stable trimers (Table 1). Thus, in contrast to the effects observed with the cavity mutations,
altering the native interhelical interaction within the glutamine layer does not substantially affect
gp41 core stability.
Expression and processing ofgp41l variants-We examined the expression and processing of
envelope mutants after transient transfection of mutant constructs into 293T cells. Transfection
efficiency, assessed by co-transfection of a GFP expression vector, was similar for all Env
proteins (T.S. and D.C., unpublished data). Western blot analysis of the cell lysates with an anti-
gp41 monoclonal antibody reveals that all gp41 mutants, except L565A, are expressed and
processed at levels similar to wild-type (Figure 3, A and B). These results are quantitated by gel
densitometry in Table 2 and are consistently similar to wild-type levels (80-120%). L565A gp41
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is expressed at 60% of wild-type. The levels of cell surface Env were quantitated by surface
biotinylation and precipitation using avidin-conjugated beads. Expression levels of mutant gp 160
and gp41 on the cell surface were similar to wild-type (data not shown) and the ratio of surface
gp41 to gp160 confirmed that proteolytic processing of the Env precursor was normal for all
mutants (Table 2).
Under normal conditions, the noncovalent interaction between gp 120 and gp41 is labile,
and a portion of gp 120 is shed from the surface of virions or Env-expressing cells. Some
mutations in gp41 affect its association with gp120, leading to increased release of gp 120 into the
culture supernatant. Immunoprecipitation of gpl20 from the culture medium followed by
Western blot analysis shows that steady-state levels of shed gp120 are similar for wild-type and
all mutants (Figure 3 and Table 2). These results further indicate that mutations at positions 565,
568, 570, and 653 in gp41 do not affect the native conformation of the envelope glycoprotein.
Fusogenic potential of mutant envelope glycoproteins-The gp41 mutants were tested for
membrane fusion activity with syncytia assays. For the N-helix mutants, there is a good
correlation between thermostability of the gp41 core and fusion activity (Table 2). The glycine
mutants, which are the least stable, have barely detectable levels of fusion. As the stabilities of
the mutants increase, there is a simultaneous increase in fusion activity. This trend becomes clear
when the fusion activity of the mutants is plotted as a function of gp41 stability (Figure 4). This
plot also reveals that the V570A mutant has unusually low fusion activity. V570A has
intermediate stability (Tm of 62°C) that is comparable to L565F, L568A, and L568F; however,
unlike these three mutants, it is severely deficient in cell fusion activity. The reason for this
anomaly remains to be determined. Our results agree with and extend previously published data
for alanine mutants at positions 565, 568, and 570 (12,14-16), which suggest a similar correlation
between fusion and core stability.
The Gln-653 mutants provide a striking exception to this correlation. Despite its highly
stable core structure, the Q653E substitution caused a 32% decrease in gp41 fusion activity
compared to wild-type. A more severe mutation, Q653L, which abolishes polarity, further
decreased gp41 function (55% of wild-type), while removal of both polarity and bulk with the
Q653A mutation almost completely abrogated fusion. These results provide the first evidence
that disruption of polar contacts within the gp41 glutamine layer decreases envelope-mediated
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fusion. The low fusogenicity of these 653 mutants despite their extremely thermostable core
structures implicates the glutamine layer in a novel role in gp41 function.
Fusion kinetics ofalanine mutants-In gp41l-mediated fusion, there is a significant lag time after
mixing cells before the first fusion events are observed (23). This delay is thought to reflect the
slow conformational changes that occur in the envelope protein during the fusion process. Our
N-helix mutants likely show fusion defects because weakened N-C helical interactions reduce the
efficiency of membrane apposition. Alternatively, it is possible that attenuated N-C helical
interactions also cause a delay in membrane apposition, resulting in a kinetic defect. In this
scenario, Env molecules would display slower-than-wild-type kinetics of fusion, leading to a
delay in the onset of initial fusion events.
To test this possibility, the L565A, L568A, and V570A mutants were analyzed further.
The alanine mutants were chosen because they display low but detectable levels of fusion. The
kinetics of fusion at early timepoints was analyzed using 3T3 cell lines stably expressing L565A,
L568A, and V570A mutant envelope glycoproteins. The alanine mutants displayed levels of
expression and processing similar to wild-type and fusion phenotypes analogous to those seen
with transient transfections (4% for L565A, 17% for L568A, and 2% for V570A) (T.S. and D.C.,
unpublished data). Dye labeling of envelope-expressing cells with a cytosolic marker, calcein-
AM, and target cells with a lipid marker, R18, allowed initial fusion events to be detected as dual-
labeled cells. For each cell line, fusion was monitored approximately every 25 minutes. Figure 5
shows the fusion progression of the alanine mutants at early timepoints after co-incubation of
effector and target cells. A small number of dye transfer events was initially detected for wild-
type gp41 between 15 and 30 minutes post-mixing, followed by a dramatic increase starting at 80
minutes. These results correspond well with reported fusion kinetics experiments, in which initial
fusion events are detected after time lag, followed by rapid acceleration ((23) and references
therein). With the alanine mutants, it is difficult to reliably measure the onset of initial fusion
events due to the low efficiency of fusion. Nevertheless, the acceleration phase for all the alanine
mutants occurs between 80 to 100 minutes, indicating that the early kinetics for wild-type and
mutant cell lines are similar.
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Discussion
Structural studies of the HIV-1 envelope protein suggest an elegant mechanism through which
gp41 mediates apposition of viral and target cell membranes: the interaction of N- and C-helices
to form the six-helix bundle forces the target cell membrane (containing the inserted fusion
peptide) close to the viral membrane (containing the gp41 transmembrane segment). If this
model is correct, the efficiency of gp41-mediated membrane fusion should depend on the strength
of the N-C interhelical interaction. Indeed, with three sets of N-helix mutants, we observe a
strong correlation between trimer-of-hairpins stability and membrane fusion (Figure 4). Fusion
activities decrease rapidly with decreased stability, and all mutants with a Tm of 570C or lower
lack significant activity, suggesting that there may be a threshold stability necessary to mediate
membrane apposition. To further test this model, it will be important to develop experimental
systems to directly measure the free energy change during the transition of gp41l from its native
conformation to its fusogenic conformation.
Our fourth mutant series at C-helix position 653 shows markedly different results and
suggests a significant role of the glutamine layer in gp41 function. Substitutions at position 653
do not significantly destabilize the hairpin but nevertheless reduce gp4 1-mediated membrane
fusion (Tables 1 and 2). Although the unusual structural features of the glutamine layer were
noted in earlier structural studies (5,6,9), this is the first evidence of a functional role for this
domain in membrane fusion.
The basis for the glutamine layer requirement remains to be elucidated. Previous
mutations in this region have not supported an essential role for this region in membrane fusion
(10-13). Interestingly, in the N-helix, residues contributing to the glutamine layer are part of a
small region implicated in resistance to the potent viral entry inhibitor enfuvirtide (reviewed in
(24), 25). Viruses containing such mutations have reduced replicative fitness in vitro, and revert
back to wild-type in the absence of inhibitor (25,26). In addition, SNARE helical bundles
involved in intracellular vesicle fusion appear to have a similar ionic layer, which may be
important for efficient recycling of SNARE complexes (27).
Numerous studies using designed coiled coils suggest that buried polar residues can play
important roles in interhelical interactions. For instance, a buried glutamine can decrease the
strength of interaction between helices (28). In addition, a buried polar residue at the interface of
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a short dimeric coiled coil can influence the orientation of the dimer, facilitating reversibility of
assembly (29); this destabilization could permit exchange of binding partners and may be
biologically relevant. While our Gln-653 mutations do not significantly change the stability or
the oligomeric state of the gp41 core, it remains to be determined whether they have more subtle
effects on gp41 protein structure.
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'The abbreviations used are: Env, envelope glycoprotein; HIV-1, human immunodeficiency
virus type 1; N-helix, N-terminal heptad repeat region of gp4 1; C-helix, C-terminal heptad repeat
region ofgp41; T,, midpoint of thermal unfolding transition.
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Table 1. Summary of Biophysical Data for N34(L6)C28-HIS Mutants.
Mutant -[T]22 Tm(103 deg cm2 dmol ' ) a (°C) 
N34(L6)C28-HIS -30.9 74 2.8
L565G -23.1 38 2.5
L565A -24.2 57 2.7
L565F -24.8 63 3.0
L568G -25.8 43 2.9
L568A -27.4 60 3.0
L568F -23.0 61 2.8
V570G -27.1 49 2.9
V570A -27.0 62 3.1
V570F -28.0 68 2.9
Q653A -30.5 74 2.9
Q653L -28.2 76 3.1
Q653E -28.9 73 3.0
a All circular dichroism wavelength scans and thermal melts were performed on 10pM peptide
samples in PBS (pH 7.0).
b Sedimentation equilibrium results are shown as the ratio of observed molecular weight (Mob)
to calculated molecular weight for a monomer (Mc).
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Table 2. Summary of Env Expression, Processing, and Fusion
Env gpl60 gp41 Cell surface gp120 Cell-cell fusion
expression a expression a gp41/gp160 b secretion (%)d
WT 1.0 1.0 1.0 1.0 100 (7)
L565G 1.2 1.0 1.0 1.0 1 (0.1)
L565A 0.8 0.6 1.0 1.2 5 (0.6)
L565F 1.2 1.1 1.1 1.3 38 (+3.1)
L568G 0.8 0.8 1.1 0.6 5 (0.6)
L568A 1.4 1.1 1.2 1.2 35 (±2.3)
L568F 1.1 1.0 1.2 1.1 32 (±1.4)
V570G 1.1 0.9 1.2 1.3 2 (0.2)
V570A 0.8 1.0 1.2 1.2 4 (0.1)
V570F 0.6 0.9 1.1 1.1 48 (±2.7)
Q653A 1.0 1.1 0.8 1.3 7 (1.7)
Q653L 1.1 1.2 1.0 1.0 55 (+6.1)
Q653E 1.1 1.1 0.9 1.1 68 (0.5)
a Relative Env expression was quantitated by densitometry. Cellular expression levels of gpl60 or
gp41 normalized to the amount of total protein in the lysate (-actin) are shown.
b Env precursor processing is measured from cell surface proteins isolated by surface biotinylation
and avidin precipitation. The reported number is the ratio (mutant gp4 I1/mutant gp160) /
(wt gp4 1/wt gp160). where wt stands for wild-type.
c The amount of shed gpl20 (sgpl20) is measured as the ratio (mutant sgpl20/mutant cellular gp41) /
(wt sgpl20/wt cellular gp4 1), where wt stands for wild-type.
d To monitor cell-cell fusion activity, Env-expressing 293T cells were co-cultured with 3T3-T4-
CXCR4 target cells for 21 hours at 370 C. Following fixation and staining, fusion events were
determined microscopically. Experiments were repeated in duplicate at least twice. The percent of
wild-type fusion in a representative fusion assay is shown. Numbers in parenthesis indicate standard
deviation. The percent of fusion for cells transfected with a control vector lacking Env is 1.4 (±0.7).
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Figure 1. Structure of the HIV-1 gp41 core.
(A) A schematic diagram of HIV- 1 HXB2 gp4 1. Important functional domains include the fusion
peptide (FP), N- and C-terminal heptad repeats (N-HR and C-HR), transmembrane domain (TM),
and the cytoplasmic tail (cyto). The sequence of the recombinant peptide N34(L6)C28-HIS,
containing N-HR residues 546-579, a six residue linker, C-HR residues 628-655, and a C-
terminal hexahistidine tag, is shown below. Residues are numbered according to their positions
in HXB2 gp160. Dots below specific amino acids indicate residues that are mutated in this study,
and highlighted glutamine and asparagine residues denote amino acids within the glutamine layer.
(B) Helical wheel representation of N34 and C28. Residues at the a and d positions of the N-
helices interact to form the interior of the trimeric coiled-coil. C-terminal helices pack against the
grooves between adjacent N-terminal helices. N-HR residues that are mutated in this study are
highlighted.
(C) The glutamine layer of HIV-l gp41. A cross-section of the gp41 core reveals glutamine and
asparagine residues from both the N- and C-HR domains that form an interconnected polar layer.
The C-helix residue Gln-653 protrudes toward the center of the six-helix bundle and is intimately
involved in the polar network. Crystallographic studies suggest that this side chain in both HIV
and SIV forms hydrogen bonds with the backbone and a glutamine residue on adjacent N helices
(6,20). These putative hydrogen bonds are shown as dashed lines.
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Figure 2. Biophysical properties of N34(L6)C28-HIS.
(A) The CD spectra of N34(L6)C28-HIS (10 riM) in PBS at 0°C.
(B) Thermal dependence of the CD signal at 222 nm for a 10 FiM peptide sample in PBS.
(C) Representative sedimentation equilibrium data for N34(L6)C28-HIS (10 jiM) in sodium
acetate buffer collected at 20 krpm and 20°C. The deviation of the data from the trimer model is
plotted in the top panel. The bottom panel shows the data and a line representing the fit using an
ideal single-species model.
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Figure 3. Expression and processing of mutant envelope glycoproteins.
(A) Expression analysis of N-helix mutant series. The top panel shows cellular gp 160 and gp41
levels detected by Western blot analysis; the middle panel indicates the 3-actin loading control;
the lower panel depicts the amount of gpl20 secreted into the culture medium.
(B) Expression analysis of C-helix mutants at position 653. Panels are the same as in (A).
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Figure 4. Correlation between gp41 core melting temperature and mutant fusion
activity.
The N-helix mutants are shown as circles (L565 series), triangles (L568 series), and squares
(V570 series). For these mutants, the symbols are black for glycine mutants, shaded for alanine
mutants, and empty for phenylalanine mutants. The Q653 series is shown as empty diamonds,
and wild-type is marked with an X. The N- and C-helix mutant series are each connected by a
line showing the correlation between Tm and fusion.
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Figure 5. Fusion kinetics of N-helix alanine mutants.
3T3 cell lines stably expressing envelope glycoprotein as well as an empty vector control were
labeled with the cytosolic dye calcein-AM. Target cells, 3T3-T4-CXCR4, were labeled with the
lipid dye R18. Following co-culture at 37°C, fusion events were detected as dual-labeled cells,
and were counted over a 3 hour time course. The fusion kinetics of wild-type (filled diamonds),
L565A (open circles), L568A (open triangles), V570A (open squares), and empty vector-
transfected (neg, filled squares) cells are shown.
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Figure 6. Cell surface expression of mutant envelope glycoproteins.
(A) Expression analysis of N-helix mutant series. Cell surface proteins were biotinylated and
precipitated with avidin. Western blots depicting cell surface gp41 is shown.
(B) Cell surface gp41 expression of C-helix mutants at position 653.
Note: This figure is not a part of the published Journal of Biological Chemistry article, but was
added as a supplement to this chapter in this thesis.
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CHAPTER 4
A CURE FOR AIDS: AN OVERVIEW
Portions of Chapter 4 will be submitted for publication (manuscript in preparation).
78
This chapter addresses scientific discoveries in HIV drug and vaccine development, novel viral
entry inhibitors, and global challenges in combating the pandemic. As a broad overview, Figure
1 shows the current state of the pandemic. There are over 39 million people living with AIDS
today. In 2004 alone, 3.1 million people died from AIDS-related illnesses. The effects of this
pandemic extend beyond public health, encompassing economic, political, and social
considerations as well. Worse, there is no end in sight.
There are eight clades, or subtypes, of the HIV-1 virus worldwide. These divisions are
based on complete genome sequence similarity. Sub-Saharan Africa, with the largest infected
population in the world, has a high prevalence of clade C virus. Clade E circulates in much of
Southeast Asia, and is also found in India and South America. The most well characterized
subtype, however, is Clade B, the HIV-1 subtype that is most prevalent in North America, the
Caribbean, and Europe.
Anti-HIV drugs
There are several classes of HIV-specific antiretrovirals (ARVs) currently available, and each
targets one of three viral proteins: reverse transcriptase (RT), protease (PR), and envelope (Env).
This section takes a chronological look at the evolution of these drug therapies and addresses
some of the challenges yet to be overcome.
In the late 1980s, within four years of the identification of HIV as the causative agent of
AIDS, the first anti-HIV drug was introduced to the market. Still in use today, azidothymidine
(AZT), a pyrimidine nucleoside analog, targets the HIV-1 reverse transcriptase (RT) enzyme,
preventing chain elongation of nascent DNA from the viral RNA template (reviewed in (14, 24,
45, 56)). AZT belongs to a class of drugs called nucleoside reverse transcriptase inhibitors
(NRTIs), in which there are currently a total of seven FDA-approved drugs. NRTIs are 2', 3'-
dideoxynucleoside analogs that require three rounds of phosphorylation by cellular kinases to
generate their active triphosphate form. A similar class of RT inhibitor is the NtRTI, or
nucleotide RT inhibitor. To date, it contains just one member, tenofovir. This drug has the
benefit of requiring only two phosphorylation steps in order to be activated. Furthermore, the
negative charge of tenofovir allows it to be more easily retained within cells. Both NRTIs and
NtRTIs compete with cellular dNTPs to bind the RT active site. A third class of RT inhibitors
contains structurally diverse compounds. They are non-nucleoside RT inhibitors (NNRTIs), and
79
most bind a pocket near the RT active site, causing an allosteric change in conformation that
inactivates the protein. Three NNRTI drugs are available for use today. Table 1 summarizes all
currently available RT inhibitors, as well as those drugs targeting other viral proteins.
The next group of ARVs to be discovered targets the HIV protease (PR). These protease
inhibitors (PIs), of which there are seven on the market, are even more effective than RTIs at
reducing viral load. Advances in structure-based drug design in the early and mid-1990s enabled
researchers to create peptidomimetic compounds that fit into the active site of the PR dimer (13).
Small peptides that mimicked PR substrates soon evolved into a diverse set of chemically
synthesized compounds (45). Like NRTIs, all presently available PIs competitively inhibit
enzymatic activity by binding the active site.
An important new class of inhibitors has recently gained much attention in the HIV field
and in the media. Prior to its introduction, available ARVs only targeted the virus after it had
already infected cells. Thus, initial infection events were permitted, allowing a pool of latently
infected cells to accumulate. A drug that prevented the infection process would clearly be a
useful complement to the arsenal of compounds that work after infection. In 2003, the first entry
inhibitor, T20 or enfuvirtide, gained FDA approval (58). It is a 36 amino acid peptide derived
from the C-terminal heptad repeat of gp4 1, and acts in a dominant negative manner to prevent the
virus from achieving membrane fusion (60). A detailed summary of other entry inhibitors
currently in development is presented below (see the Inhibiting viral entry section).
The availability and use of ARVs has made a substantial impact on reducing the mortality
of AIDS patients. For example, pre- and post-natal administration of these drugs to HIV-positive
mothers has greatly reduced the incidence of mother-to-child transmission of HIV (22). In the
North America and Europe, AIDS-related hospitalizations and deaths have markedly declined
(14).
Drug therapy, however, is not a sustainable solution to the HIV and AIDS pandemic.
The most formidable obstacle presented by drug therapy is the development of drug-resistant HIV
strains. Initial attempts to reduce viral load with monotherapy quickly led to the emergence of
drug-resistant strains, often within weeks of administering the drug (4, 14). As a result, HAART,
or highly active antiretroviral therapy, has become the norm for drug therapy regimens (13, 14,
45). A combination of three or more ARVs (from the RTI and PI classes) is co-administered, and
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the result has generally been successful. When resistance does appear, as it almost always does,
patients simply switch to another drug within the same class. Unfortunately, some patients have
run out of options. Potential complications with HAART include antagonistic drug interactions,
the emergence of multidrug resistant strains, and numerous noxious side effects. Furthermore,
while patients with access to HAART are certainly fortunate, they are subjected to an extremely
rigorous and demanding dosage schedule that has undoubtedly contributed to patient
noncompliance. Some researchers stress the danger of drug-resistant strains that are emerging as
patients abandon their drug regimen. Novel HIV inhibitors, such as enfuvirtide, and experimental
drugs targeting other viral enzymes (such as integrase) and processes (such as Rev-mediated
nuclear export and viral assembly), will provide much needed hope for attenuating disease
progression (45).
Finally, this section has only addressed HIV-specific drugs. Since the ultimate cause of
disease and mortality in AIDS patients is opportunistic infection, there are many attempts to
target those diseases (such as tuberculosis, Kaposi's sarcoma, and Pneumocystis carinii
pneumonia) and the immune system itself. Immune system stimulants such as interferons and
cytokines boost host defense responses and inhibit viral replication (46). Two promising
candidates, recombinant interleukin 2 (IL2) and interleukin 7 (IL7), have been shown to raise
CD4 cell counts and stimulate latent proviruses in AIDS patients (14, 59).
The search for a vaccine
To truly reduce HIV/AIDS-related morbidity and mortality, a preventative vaccine is urgently
required. The best-case scenario would be a vaccine that prevents infection in challenged
patients, i.e. one that elicits sterilizing immunity. However, there is also significant benefit to a
vaccine that boosts the host immune defenses, perhaps to the point where plasma viremia are
cleared and persistently infected cells are destroyed. In fact, even a vaccine that enables the body
to fully function with a basal level of infection would dramatically reduce the effects of the AIDS
pandemic.
There are several approaches being taken to develop an HIV vaccine (these are reviewed
in (3, 11, 13, 51, 53)). Subunit vaccines that are composed of recombinant viral proteins, usually
Env, are intended to stimulate a humoral (antibody) response. B cells that recognize these viral
antigens produce antibodies that neutralize free virions in the bloodstream. The most notable
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example of a subunit vaccine-as well as the most advanced candidate in clinical trials to date-
is a gp120 vaccine developed by the Genentech spin-off company VaxGen (51). Initial
immunization with a single laboratory-grown (or lab-adapted) strain of HIV gp120 did not protect
people from HIV infection in Phase II trials and, as a result, gpl20 from a second, more virulent,
strain was added. This 'bivalent' vaccine, termed AIDSVAX, was tested in clinical trails in the
United States and Thailand in the late 1990s and early 2000s. Unfortunately, neither AIDSVAX
alone or in combination with other candidate vaccines (termed the prime-boost approach, see
below) has yielded promising results for the gp120 subunit vaccine. In fact, continuation of
AIDSVAX drug trials in the face of negative results has caused some disharmony in the scientific
community; the best way to integrate basic science, clinical trials, and procedural issues related to
vaccine development is still being debated (12). Currently there are no subunit-only vaccines in
development. Attempts to generate an antibody response to the virus are being made through
other approaches, such as DNA vaccines (see below).
Vector-based vaccines, on the other hand, stimulate the cellular immune response. They
consist of recombinant viruses or bacteria (in both replication-competent and replication-
incompetent forms) that express HIV proteins. Host cells infected by these vectors stimulate
cytotoxic T lymphocytes by presenting HIV antigens on the cell surface. In addition, vectors
circulating in the bloodstream are also capable of eliciting a humoral response. A promising
approach combining a vector-based and a subunit vaccine that present the same antigen is
currently being investigated in clinical trails. In this 'prime-boost' approach, patients are
typically initially immunized with a subunit protein, followed by an immune system 'boost' with
the live vector (38, 51, 53). The most popular vectors in use are canarypox- (ex. ALVAC),
vaccinia- (ex. MVA), and adenovirus- (ex. AdS) based.
Other approaches to vaccine development include whole-killed viruses, or live-attenuated
viruses. While these approaches have been effective in combating diseases such as polio, rabies,
and measles, they are met with reasonable and justified skepticism in the HIV field. Preparations
of whole-killed virus usually involve inactivation of live virus by chemicals or irradiation (51). If
any infectious virus remains after this treatment, the inoculum may indeed cause HIV infection in
naive patients. One controversial vaccine, Remune, which consists of inactivated HIV, is
currently in clinical trials and is being used to stimulate the immune response of HIV-positive
individuals (52, 56).
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A novel and intriguing type of vaccination is the DNA vaccine. Circular DNA encoding
one or more viral proteins under the control of a strong promoter is injected intramuscularly or
subcutaneously (21). In a process that is not fully understood, the naked DNA is taken up by
cells and integrated into the host genome. Antigenic proteins are then expressed on the cell
surface. While the method and repercussions of viral DNA uptake and integration into the host
genome are unknown (and may potentially be harmful), many DNA vaccines are currently in
various phases of clinical trials (53). Although DNA vaccines alone yield poor cytotoxic and
humoral immune responses, when coupled with adjuvants or used in a prime-boost combination
they may generate a substantial immune response (2). The major advantage to such an approach
is the ease and low cost of preparation; if successful, this method would be extremely useful in
developing countries.
Macaques (typically rhesus monkeys) are the most commonly used animal in vaccine
studies (24, 51). Simian immunodeficiency virus (SIV) is closely related to HIV, but does not
cause AIDS-like disease in the natural host. Macaques infected with certain heterologous,
pathogenic SIV strains however do show AIDS-like syndrome. Furthermore, researchers have
determined that a chimeric virus, termed SHIV, consisting entirely of SIV proteins with the
exception of an HIV envelope, can reliably cause disease in Asian macaques (24). In fact, some
extremely virulent SHIV strains, obtained by repeated passaging in animals, cause CD4 T cell
depletion within one month of infection and death within three to four months. The rapidity of
disease progression, and the fact that these chimeric viruses present the HIV envelope protein,
makes this animal model particularly well-suited to vaccine studies.
The experimental parameters and protocols used in animal studies are still being
developed. For instance, two factors appear to reproducibly influence the outcome: the time and
the mode of challenge following vaccination (16). The immune response is strongest shortly after
the final vaccine boost, and therefore most studies are initiated at this time. In addition, mucosal
challenge typically elicits a stronger immune response than intravenous challenge (51).
Unfortunately, even when both parameters are optimized, few vaccine candidates elicit a response
strong enough to combat pathogenic viral strains.
The drawback to using non-human primates as a model system is that they do not
accurately reproduce the human immune response. The dose of challenge virus used in monkey
studies far exceeds the dose of a typical HIV infection in humans. Thus, the danger is that
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potentially useful human vaccines may be undetected if they fail to prevent SHIV infection in
monkeys. Furthermore, as a necessity to studying vaccines in monkeys, animals that rapidly
develop AIDS-like symptoms (within months) are used. However, the human immune system is
able to prolong the onset of AIDS for decades. Thus, again, the requirements for an effective
animal vaccine may be more stringent than what is needed for a successful human vaccine.
In addition to these hurdles, HIV vaccine researchers face other significant challenges.
Despite considerable efforts, the level and type of immune response necessary to reduce disease
progression, i.e. the correlates of immunity, are not known. There is much debate about which
arm of the immune system is necessary to achieve protective immunity: the T-cell mediated
cytotoxic response or the humoral arm with antibody-mediated immunity (reviewed in (44)). To
date, each type of response has demonstrated an ability to control infection as well as
vulnerability to viral trickery.
The cellular immune response is of paramount importance in clearing infected cells that
are potential factories for virus production. The discouraging AIDSVAX trials revived an interest
in cellular immunity. Vaccination of macaques with a modified vaccinia Ankara (MVA) vector
has reduced viremia and delayed disease progression upon challenge with SIV (43). Similarly,
canarypox vaccines elicit a modest cytotoxic cell response, replication-defective alphavirus
vectors target and stimulate antigen-presenting cells, and intranasal delivery of replication-
competent adenovirus elicits some systemic and mucosal immunity in primates (38).
Interestingly, studies in macaques show that immunization with an attenuated pox vector
(expressing SIV Env, Pol, and Gag) in combination with antiretroviral therapy stimulates host
immunity (38) more than immunization alone. This opens a new avenue of exploration in which
drug suppression of viral replication can be used to sustain and strengthen immune defenses. In
addition, viral vectors in a prime-boost combination with DNA or subunit vaccines are being
actively studied (44). The most compelling reason to pursue cell-based immune strategies comes
from broad-based protection of monkeys immunized with live attenuated SIV (16). Similar
experiments with a variety of attenuated SIV strains are showing, however, that the immune
system may only be capable of controlling challenge from a homologous strain (17). While it is
doubtful that live attenuated vectors will be used as an HIV vaccine, due to safety concerns, the
correlates of immunity in these animals are being intensively investigated.
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Most existing vaccines (such as those for rabies, influenza, hepatitis A and B, and polio)
invoke antibody-based protective immunity (44). The most convincing evidence that this
approach will work for HIV is that passive transfer of neutralizing antibodies in macaque
monkeys confers protection against subsequent viral challenge (37, 39). Although the level of
serum antibody in these experiments exceeds the titer produced by vaccination, these studies have
generated much hope and interest in humoral immunity. However, generating an antibody
response with broadly neutralizing capability remains a significant challenge. Most antibody
responses are specific to the immunization strain, and do not neutralize heterologous, challenge
virus (17). Notably, a few gp41 monoclonals provide exception to this general rule, and are being
extensively studied (see Inhibiting Viral Entry, below).
The route of infection is yet another complicating factor in developing a vaccine. An
ideal vaccine would target and stimulate an immune response where it is most needed. For
example, since the majority of HIV transmission is through heterosexual intercourse, mucosal
cells lining the vaginal wall are important first defenses in an anti-HIV response. In this case,
stimulation of immunoglobulin A (IgA) antibodies in mucosa is essential. HIV can also be
transmitted from mother to newborn child during childbirth or breastfeeding. While
antiretrovirals have virtually eradicated mother-to-child transmission in developed nations,
approximately 30% of HIV-positive African women transmit the virus to their children (32, 55).
A combination of drug therapy and a preventative vaccine may reduce this transmission
worldwide.
The last two years have seen an unprecedented rise in the number of candidate vaccines
entering human clinical trials (28). As of January 2005, there were twelve ongoing HIV vaccine
trials and eleven trials in various planning stages (53). Even more encouraging, in 2003, the first
clade C-derived candidate vaccine moved into clinical trials (see Figure B for the worldwide
distribution of HIV clades or subtypes). The clade C subtype of HIV predominates in South
Africa which has the largest infected population in the world. Until recently, most basic science
and clinical trials have been performed with clade B virus, which is more prevalent in developed
countries. In order to mount an effective response to HIV and AIDS, scientists will have to study
and target the globally predominant viral subtypes.
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Viral immune evasion
Researchers face a formidable opponent in the HV virus and, despite over two decades of
intensified research efforts, AIDS remains a deadly disease. HIV employs several unique
strategies to evade the host immune system, four of which are outlined here.
A staggering mutation rate is one of the virus's primary defense mechanisms.
Approximately 109 to 1010° virions are generated every day in an infected patient, and the mutation
rate, due to sloppy proofreading capability of RT, is about 3 x 10-5 per nucleotide per replication
cycle (30). This allows the virus to continually experiment with different combinations of
mutations and, not surprisingly, is the major reason for the rapid evolution of drug resistant
strains. In addition, there is another twist in the virus's ability to mutate: recombination between
variant strains in a single infected host. This in vivo recombination occurs in doubly infected
cells and can lead to great genetic variability. The global emergence of these circulating
recombinant forms is a significant and threatening source of multi-drug resistant viruses.
Furthermore, HIV primarily infects CD4 T cells, macrophage, and dendritic cells, the
very cells that normally effect the immune system's response to a pathogen (13, 30). Early in
infection, viral strains are typically macrophage- or M- tropic. They utilize the CCR5 coreceptor,
and are nonsyncytium inducing. Later, just before the patient develops full-blown AIDS, the
virus often evolves into a more virulent T-tropic strain that infects CD4 T cells, uses the CXCR4
coreceptor, and induces syncytia formation (18). Depletion of these immune cells, directly and
indirectly caused by viral infection as well as by cytotoxic responses, weakens the immune
response and leaves the host vulnerable to opportunistic infections.
HIV is capable of infecting nondividing cells and the provirus can remain quiescent for
long periods of time. Antiretrovirals are able to suppress active viral replication, and a vaccine
may potentially destroy dividing infected cells. But, the reservoir of persistently infected cells is
invisible to the immune system and will always be able to produce progeny virus (13). Ideally, a
long-term solution to fighting HIV infection will involve destruction of this deadly pool of cells.
Finally, the most visible portion of the virus to the humoral immune system is the
envelope glycoprotein and the majority of anti-HIV antibodies are directed against Env.
Extensive glycosylation of gp 120, accounting for about half of its molecular weight, shields
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important functional domains, such as receptor and coreceptor binding sites, from antibody
binding. As a result, the ability of the humoral immune system to generate neutralizing
antibodies is greatly hindered.
Inhibiting viral entry
One of the most powerful ways to prevent the spread of the HIV pandemic is to inhibit early
infection events. As stated above, once infection is established, it is extremely difficult to remove
the pool of latently infected cells from the body. This section discusses the different avenues
being explored to impair the function of the envelope protein, as summarized in Figure 2.
Since gp 120 facilitates initial contact between virus and host cell, it is a logical target for
anti-HIV drugs. gp120 contains five regions of variable sequence (V1-V5) that are interspersed
with five constant domains (C1-C5) (Figure 3). Initial adhesion of the virion to host cells occurs
through an ionic interaction between the positively charged gp 120 V3 loop and the negatively
charged cellular heparin sulfate proteoglycans, lectins, and adhesion factors (41). Several
polyanionic and cationic molecules block viral attachment in vitro, but only one, AR177 or
zintevir, has progressed to clinical trials so far (45). Semi-specific inhibitors of attachment may
be enormously useful as topical microbicides.
The binding site for CD4, the major cell surface HIV receptor, is a recessed pocket that is
shielded by heavily glycosylated variable regions. The gp120 C3 and C4 domains make several
contacts with CD4, but the entire binding surface is discontinuous and contains other gp 120
regions. Initial attempts were made to block the CD4-gp 120 interaction using soluble CD4
(sCD4); however, this monomeric molecule only exhibited antiviral activity against laboratory-
adapted HIV strains, and not the more virulent clinical isolates (41). A multimer of soluble CD4
domains tethered together via a tetrameric immunoglobulin domain led to the development of
CD4-IgG2 or PRO 542, an antagonist of the CD4-gpl20 interaction (29). This molecule is
currently in drug trials. In addition, monoclonal antibodies against CD4 also inhibit fusion. One
example is TNX-355, which is administered intravenously and inhibits a broad range of clinical
isolates (45). In 2003, the compound BMS-378806 was reported to bind specifically to the CD4
binding pocket of gp 20, based on competitive inhibition experiments (26). Subsequent studies
reported resistant mutations and indicated that BMS-378806 may bind near, but not directly in,
the CD4-binding pocket and may perhaps influence gpl20-gp41 interactions (48). A recent
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structure of SIV gp120 in its native, unliganded form (9, 10) suggests that this compound likely
binds a groove in gpl20 that eventually forms the CD4-binding pocket. BMS-378806 is
currently being evaluated in clinical trials. Finally, cyanovirin-N (CV-N), a protein from the
cyanobacterium N. ellipsosporum, is another potent viral inhibitor. It targets specific N-linked
oligosaccharides on gpl20 and an encouraging result shows little development of resistance to
this protein (45).
Inhibiting gpl20-coreceptor interaction is an attractive option for preventing viral entry,
since a small group of people with a CCR5 mutant allele are extremely resistant to HIV infection
yet are otherwise healthy (see Rare cases of resistance, below). There are about twelve
coreceptors for HIV in vitro, although two (CCR5 and CXCR4) are most commonly used in vivo
(41). These molecules belong to the seven-transmembrane-spanning G-protein-coupled receptor
family and function by binding chemokines and sending downstream signals that dictate cellular
migration patterns. While the natural chemokines (such as RANTES, MIP-la and -13 for CCR5
and SDFI for CXCR4) can potentially inhibit fusion, their function is to downregulate their
receptors and initiate cellular signaling (41). These undesired effects make such ligands
unpromising anti-HIV drug candidates; nonantagonistic chemokine derivatives and antibodies are
better options. Two promising antagonists of the gp120-CCR5 interaction are PRO 140, an anti-
CCR5 antibody, and TAK-779, a small molecule that binds a CCR5 cavity and induces
conformational changes that preclude gp120 binding (41, 45). Neither compound initiates
downstream cellular signaling. Similarly, a CXCR4 antagonist, the bicyclam AMD3100, is
showing promising results in early clinical trials. This molecule may prevent the virus from
switching from the less pathogenic CCR5 coreceptor to CXCR4, as is often seen immediately
prior to the onset of AIDS (18). An AMD3 100 derivative, AMD3465, is even more potent at
inhibiting CXCR4 virions (45). Blocking gpl20-coreceptor interactions is indeed a promising
avenue to explore, but some caution will be necessary so that directed viral evolution toward a
more virulent CXCR4-tropic strain is not an unwelcome byproduct.
The process of gp4 1-mediated viral fusion is well studied. Mutagenic studies, such as the
one described in Chapter 3, have highlighted critical residues and regions necessary for gp41
function. Using the available gp41 x-ray structures, potent peptide inhibitors, such as IQN26
(Chapter 2) have been designed to specifically target fusion pathway intermediates. gp41
epitope-mapping and in vitro biochemical analyses are also used to further dissect the fusion
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pathway. A detailed understanding ofgp41 conformational changes during fusion is emerging,
and is being used to design gp41 inhibitors.
Enfuvirtide, or T-20, has been a promising and welcome addition to the antiretroviral
lineup (see the Anti-HIV Drugs section, above). While this entry inhibitor, corresponding to a 36
amino acid region of the gp41 C-HR, is the first of its kind on the market, there are numerous
candidates in the pipeline. A second-generation peptide inhibitor that partially overlaps T-20,
called T-1249, is ten times more potent in vitro (45). T-1249 is a 39 amino acid peptide
composed of C-HR sequences derived from HIV-1, HIV-2, and SIV (20). In January 2004,
ongoing early clinical trials of this drug were halted in order to improve the formulation of the
product; they are expected to resume once production concerns are resolved (57). In addition,
numerous small molecule entry inhibitors are being designed and screened for the potential to
bind the gp41 cavity (15, 19, 23, 31). Although none are currently in clinical trials, these non-
peptidic small molecules may be better suited for antiretroviral therapy.
Systematic analyses of gp41 have been used to generate chimeric, helical N-peptides,
such as IQN26, that have inhibitory activity in vitro. One interesting molecule, consisting of
three N-helices surrounded by two C-helices, forms a stable six-helix-bundle-like structure that
exposes a single C-helix binding site. This recombinant protein, 5-helix, is another potent in vitro
inhibitor (47). Limited bioavailability and the need to inject peptide inhibitors once or twice daily
may hinder the potential of 5-helix and other recombinant peptides as long-term, mainstream
fusion inhibitors. However, they may be used as leads to develop nonpeptidic derivatives or as
mimics of gp41 intermediates that could serve as screening agents for more effective compounds.
In addition, modified versions of such compounds may be useful as immunogens (47).
Env is the most visible viral protein to the immune system; it is therefore the subject of
many vaccine trials and studies. Antibodies can neutralize the virus by binding to important
functional domains and thus sterically blocking virus-cell interactions. Most HIV antibodies
generated by natural infection or immunization have limited or no neutralizing capability.
Antibodies that do neutralize a broad spectrum of clades are rare, and once found, their epitopes
are difficult to reproduce. There are currently five known broadly neutralizing antibodies against
the Env glycoprotein, all derived from individual HIV patients (reviewed in (6)). The first one
identified was b12. a gpl20-binding antibody that occludes the CD4 binding site via a long
protruding loop on the antigen-binding fragment Antibody 2G12 also binds gp120. It is unique,
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however, in that it recognizes not only peptidic but also glycan moieties on the gp120 surface.
Three other monoclonal antibodies, 2F5, 4E10, and the very similar Z13, recognize adjacent
epitopes of the gp41 C-HR region. These antibodies appear to bind more tightly to the native
conformation of gp41 rather than the CD4-triggered conformation (40). A recent crystal structure
of 4E10 with a 13 residue gp41 peptide shows this tryptophan-rich C-HR region to be helical (7).
To date, 4E10 is the most broadly neutralizing antibody known. Since designed immunogens
mimicking the C-HR have repeatedly failed to elicit a neutralizing response, identification of the
4E10 epitope structure will certainly aid vaccine design efforts.
The potential to target antibodies to gp41 intermediates, such as the prehairpin structure,
has been tantalizing yet controversial. This approach could face one of two major potential
problems. The first is the question of steric hindrance-i.e., can an antibody fit in the space
between virus and cell, and can it access exposed N-HR or C-HR regions in the presence of
gpl20 and nearby cell-surface proteins? Some evidence, using a series of cargo proteins attached
to a potent inhibitor that binds the N-HR region, indicates that a -150 kDa antibody may be
sterically occluded from binding the N-HR region (27). Second, the transient exposure of the
prehairpin intermediate could kinetically prevent antibody binding. Some groups report in vitro
binding and neutralizing activity of anti-N-HR antibodies only at suboptimal temperatures (25).
However, antibodies from HIV-positive individuals react with peptide mimics of the N-HR
region (very similar to IQN26, described in Chapter 2), some of which may possess multi-strain
neutralizing capability (27, 42). gp41 is indeed a difficult protein to biochemically characterize,
given its labile native structure (that is largely shielded by gp120) and its dramatic conformational
transitions. While the N-HR region is an attractive target due to its sequence conservation and
the presence of the hydrophobic cavity, a well-established drug target, scientists will need to
become increasingly creative to generate a broadly neutralizing response to these transiently
exposed structures.
The biophysical work presented in Chapter 2 suggests that the N-HR region may not be a
uniform, stable trimer throughout its length. Whereas hybrid peptides containing the hydrophobic
cavity are better inhibitors when they are extremely thermostable and trimeric, a chimeric peptide
containing the N26 region only interacted with C-HR and inhibited fusion in a less stable form
(see Chapter 2). If further biochemical studies confirm that the N26 region is a weak trimer,
perhaps inhibitors that intercalate into this region of the N-HR could be designed. Even if they
90
are not effective immunogens, hybrid peptides that accurately mimic gp41 intermediates could
greatly facilitate drug screening.
Furthermore, this chimeric peptide strategy need not be limited to N-HR-derived
peptides. The few broadly neutralizing antibodies available today all bind the C-HR region in a
native conformation (see above). Since structural analysis of antibody 4E10 shows its C-peptide
epitope to be helical, hybrid molecules similar to IQN26 that stabilize the C-peptide may be even
more useful immunogens.
The mutagenesis experiments described in Chapter 3 show that six-helix bundle
formation drives membrane fusion. Further confirmation of this model will come from a mutant
that is more fusogenic than wild-type Env and also has a more stable six-helix bundle structure.
In addition, the effect of these substitutions on gp41 structure can be better studied through the
use of longer N- and C- peptides that are not covalently attached to each other (unlinking the
peptides may potentially reveal improper helix alignment). The N-HR glycine, alanine, and
phenylalanine mutants described in Chapter 3 are likely to be arrested at the prehairpin
intermediate state. This hypothesis could be confirmed by assessing fusion kinetics in the
presence of C-peptide inhibitors or by immunoprecipitation with antibodies directed against non-
cavity N-HR residues (the mutations are all within the cavity). If the prehairpin intermediate is
indeed sterically accessible to antibodies (see above), then a vector-based vaccine containing an
Env mutation (similar to those in Chapter 3) may allow prolonged exposure of this intermediate
to the immune system. Given the difficulties inherent in generating a prehairpin-like immunogen,
viral vectors that present prehairpin-arrested Env may be worth exploring. The glutamine layer is
an intriguing target, and further mutagenesis and biochemical studies will be useful in elucidating
its role in gp41-mediated fusion. This highly polar segment of the mainly hydrophobic N-C
interface may be an attractive drug target.
Several important questions in the membrane fusion field remain unresolved. For
example, how does the prehairpin intermediate actually resolve into the six-helix bundle
structure? There is an inherent problem of topology. If all three C peptides extend toward the
target membrane symmetrically, 120° apart from each other, and simultaneously interact with the
trimeric N-HR, the viral membrane would surround the N-C linker and the newly-formed six-
helix bundle. However, studies with influenza HA and HIV Env suggest that the six-helix bundle
remains anchored on the outside of an infected cell (50, 61). It is therefore likely that N-HR
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interacts with the three C-helices sequentially. If this occurs, it is unknown whether all three C
helices, or just one or two, have to interact with the N-HR in order for the attached membranes to
merge. Some studies suggest that six-helix bundle formation may even occur after formation of a
small pore between virus and cell (36). An understanding of this process may lead to better
design of inhibitors; for instance, tethering two or more C peptides together may increase their
potency.
A monumental advance in the membrane fusion field will come from the determination
of the gp41 native state structure, and if at all possible, the prehairpin intermediate. Undoubtedly,
much of native gp41 is shielded by gp120 and a few C-terminal glycan moieties. However, the
most potently neutralizing HIV antibodies to date target the C-HR of gp4 1, most likely in a native
conformation. A native state structure would provide critical hints about the conformational
transitions that gp41 undergoes to reach the six-helix bundle. The prehairpin intermediate is
perhaps the most promising gp41 target, and it will be important to definitively answer the
question of steric accessibility. Molecules that mimic its transiently exposed trimeric structure
will serve as immunogens and useful screening agents. Hybrid peptide strategies such as the one
discussed in Chapter 2, are currently being used and can be improved upon. For example,
measures can be taken to reduce the immune reactivity of the scaffold peptide moiety of these
immunogens, such as by surface glycosylation. Alternatively, the outer surface of the scaffold
peptide can be engineered to more closely resemble the gp41 trimer (such as in (49)). Atomic
resolution structures of Env will certainly advance the rational design of anti-HIV drugs with
improved binding to the native or intermediate gp41 structures.
Rare cases of resistance
During the 8-10-year period of clinical latency, there is usually a steady decline in the level of
circulating CD4 T cells. However, in some rare cases, this decline is not observed, and patients
can live up to twenty years or more after infection. The basis for these long-term nonprogressors
is unknown. Some sex workers in Kenya and Gambia, for instance, have remained persistently
seronegative despite continuous exposure to the virus (30, 34). They have a vigorous cytotoxic
immune response that often recognizes unmapped epitopes. Although some 'resistant' workers
eventually do succumb to the disease, they are being carefully studied and provide hope that a
vaccine may confer substantial immunity to HIV and AIDS.
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Additionally, individuals homozygous for a 32 base pair deletion in CCR5 (A32 allele)
are highly HIV-resistant, while heterozygotes demonstrate slower progression to AIDS than
normal (1). The 32 base pair deletion occurs in an extracellular loop between transmembrane
regions four and five of the seven-transmembrane chemokine receptor, and prevents cell surface
expression of the mutant protein. CCR5A32 may also interact with and downregulate surface
expression of other HIV coreceptors (such as CXCR4), further enhancing cellular resistance to
viral infection.
Finally, infection with HIV-2, a less virulent and transmissible virus that causes slower
disease progression, has been shown to reduce the progression and severity of HIV-1 associated
disease (30). Some studies indicate that the basis for this protection is that HIV-2 stimulates
production of f3-chemokines that are CCR5 ligands (35). Thus, establishment of infection with
M-tropic HIV-1 strains that utilize the CCR5 coreceptor is reduced. The humoral and cellular
responses to HIV-2, and their cross-reactivity with HIV-1, are under investigation.
Successful strategies
Rising mortality rates and an awareness of the serious health and economic impact caused by
AIDS are fueling many significant global efforts to combat the epidemic. A 2003 AIDS Pipeline
Project group meeting cites cooperation between many international health agencies. Among
them are The Global Fund to Fight AIDS, TB, and Malaria, the Millennium Challenge Account,
the World Health Organization 3 by 5 Initiative, the Global Alliance for Vaccines and
Immunization, and the International AIDS Vaccine Initiative.
Uganda has been heralded in the media for turning around its AIDS crisis and
dramatically lowering infection rates despite its limited resources (33, 54). The ABC approach of
'Abstinence, Be Faithful, and Condomize' has successfully spread the message of prevention to
younger generations of Ugandans. The president, Yoweri Museveni, and other high-level
government officials have made HIV/AIDS prevention, care, and treatment programs a top
priority. Indeed, individuals from all sectors of society-religious leaders, school teachers,
community groups-have committed to action. The Ugandan fight against AIDS involves sex
education programs in schools, aggressive marketing of condoms (at prices subsidized by the
government and other health organizations), and promotion of an STI (sexually transmitted
infections) self-treatment kit. Same-day testing and counseling services, launched in 1997, have
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not only become widely used, but are also a way to recruit and train peer educators. Importantly,
these efforts have also succeeded in lowering the barriers of social stigma that so often hinder
care and treatment programs.
The results have been remarkable. Since the early 1990s, infection rates among pregnant
women have declined by more than 50% in some areas of the country. According to the World
Health Organization, HIV infection rates among men attending STI clinics fell 16% between
1992 and 1998. Condom use is higher than 50% in rural areas, and over 85% in urban areas. The
prevalence of HIV in teenage girls has dropped from approximately 4.5% in 1990 to less than 1%
in 1997 (54).
The encouraging downward trend in HIV infection is not limited to Uganda. Thailand is
also controlling the spread of HIV by social awareness programs and condom marketing. In both
Thailand and Senegal, sex workers are reporting increased condom usage.
Even in these countries, of course, much work remains to be done-poverty, gender
inequality, and the growing number of AIDS orphans are serious problems. Mother-to-child HIV
transmission can be dramatically reduced in developing countries with ARVs, as it is in the North
America and Western Europe. Drug and vaccine distribution also poses some obstacles. Many
developing nations lack the infrastructure to provide HIV testing and counseling, treatment, and
in the future, vaccines, to infected people. Currently, global health and funding organizations are
making progress toward addressing this issue. In addition, despite the low profitability of
developing HIV vaccines, some drug companies are nevertheless conducting clinical trials and
establishing partnerships in developing nations to eventually distribute ARVs and vaccines.
The dedication and leadership of political, community, and health groups in countries like
Uganda powerfully demonstrates that concerted effort can alleviate the AIDS crisis. The success
of these approaches, combined with continual scientific progress in HIV drug and vaccine
development, provide much hope that the AIDS pandemic will someday fade into the pages of
human history.
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Future prospects
After several years of conducting research on gp41, I have come to appreciate the complexity of
the virus and, especially, the entry process. In terms of targeting the virus in order to curtail the
spread of this pandemic, I believe that viral entry has the most promising potential. This is
because: (1) No other HIV protein is as visible to the immune system, or as immunogenic. Thus,
Env can be effectively attacked on two fronts, as a drug and as a vaccine target, to mitigate the
effects of resistant mutations. (2) Reducing initial fusion events in a newly infected person will
greatly reduce the number of latently infected cells. I see these cells as one of the major obstacles
to truly 'curing' AIDS. Unless they are removed, there is always the potential to destroy CD4
cells and develop immune deficiency. (3) Portions of Env, mostly the gp41 rev response
element-encoding sequence and the N- and C- heptad repeats (including the glutamine layer
residues) are highly conserved among the diverse clades. Therefore, we have the best chance to
use the same antiviral strategy for diverse HIV strains if this protein is targeted.
Every step taken toward understanding the mechanistic details of the fusion machinery is
vital, applicable, and necessary. Mutagenic studies (Chapter 3) indicate that even conservative
mutations in this fusion machinery can greatly impair function. Furthermore, this study suggests
a novel gp41 subdomain, the glutamine layer, may be critical to gp41 activity. It is intriguing that
a potent peptide inhibitor, T20, can be made tenfold more effective by reengineering its sequence
to include conserved HIV-1, HIV-2, and SIV residues (and by lengthening it by three amino
acids). Perhaps by combining these two approaches-mutagenesis to identify critical residues
and sequence alignment to identify conservation-HIV antigens and peptide inhibitors can
become more potent.
An HIV vaccine that confers sterilizing immunity is highly unlikely. Encouraging results
with live attenuated SIV and passive antibody transfer in monkeys suggest that a vaccine that
reduces disease progression is attainable. A truly effective vaccine will have to stimulate both the
cytotoxic and humoral arms of the immune system. The most promising avenue for vaccination
is the prime-boost approach, although this method will require administering two separate
immunizations several months apart. In addition, it will not be possible to generate a single-strain
vaccine that effectively neutralizes a broad spectrum of clades. A broadly-neutralizing vaccine
will likely contain components of at least two HIV strains or clades, an approach taken each year
with the flu vaccine (8).
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On a global scale, increased efforts and resources are being devoted to HIV/AIDS
prevention and education programs, distribution of ARVs, and the establishment of care and
treatment facilities. The substantial scientific research efforts outlined here, aimed at
understanding the viral fusion machinery, will also certainly contribute to the fight against HIV
and AIDS. Progress in this direction has already led to the development of antiviral drugs that
ease suffering and prolong lives. Now, a vaccine that reduces disease progression and
transmission is the next challenge, and perhaps the most powerful way to mitigate the impact of
HIV and AIDS worldwide.
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Table 1: Summary of anti-HIV drugs a
Year
Drug Name Trade Name Target / Class c Company approved
Zidovudine (AZT, ZDV) Retrovir Reverse Transcriptase / NRTI GlaxoSmithKline 1987
Didanosine (ddI) Videx (nucleoside inhibitors) Bristol-Myers Squibb 1991
Zalcitabine (ddC) Hivid Hoffmann - La Roche 1992
Stavudine (d4T) Zerit Bristol-Myers Squibb 1994
Lamivudine (3TC) Epivir GlaxoSmithKline 1995
Abacavir (ABC) Ziagen GlaxoSmithKline 1998
Emtricitabine (FTC) Emtriva Gilead Sciences 2003
Tenofovir Viread NtRTI (nucleotide inhibitor) Gilead Sciences 2001
Nevirapine (NVP) Viramune Reverse Transcriptase / NNRTI Boehringer Ingelheim 1996
Delavirdine (DEL) b Rescriptor (non-nucleoside inhibitors) Agouron Pharmaceuticals 1997
Efavirenz (EFV) Sustiva Bristol-Myers Squibb 1998
Saquinavir (SQV) Invirase. Fortovase Protease Hoffmann - La Roche 1995
Indinavir (IND) Crixivan Merck Pharmaceuticals 1996
Ritonavir (RIT) Norvir Abbott Laboratories 1996
Nelfinavir (NEL) Viracept Agouron Pharmaceuticals 1997
Amprenavir (AMP) Agenerase GlaxoSmithKline 1999
Lopinavir, Ritonavir Kaletra Abbott Laboratories 2000
Atazanavir Reyataz Bristol-Myers Squibb 2003
Enfuvirtide (T-20) Fuzeon Env Hoffmann - LaRoche 2003
a This list is a compilation of data from the U.S. Food and Drug Administration (www.accessdata.fda.gov, reference 58). the AIDS Education Global
Information System (www.aegis.com), and from reference 14.
b Only available in the United States.
c Classes of inhibitors are divided into nucleoside and nucleotide reverse transcriptase inhibitors (NRTI and NtRTI, respectively). non-nucleoside reverse
transcriptase inhibitors (NNRTIs), protease inhibitors, and envelope inhibitors.
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Figure 1. The global impact of HIVIAIDS.
(A) Adults and children estimated to be living with HIV at the end of 2004. Sub-Saharan Africa
is currently at the heart of the pandemic, although Southeast Asia, India, and Latin America have
alarming rates of infection. These data are from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) / World Health Organization Report on the Global AIDS Epidemic,
December 2004 (http://www.unaids.org).
(B) Prevalence of HIV clades worldwide. The three genetic subtypes of HIV are designated M
(for major), O (for outlier), and N (for non-M and non-O). The M group includes over 95% of all
viral isolates worldwide, and is divided into eight clades (A, B, C, D, F. G, H, and J. Note that
Clade E is a circulating recombinant form.) based on the sequence of complete viral genomes.
Viruses belonging to the O group have been detected primarily in patients from West Africa, and
those in the N group have been discovered only in certain patients from Cameroon. The clade
distribution of group M isolates is shown here, with the predominant clade in a geographical
region indicated by a large circled letter. The distribution map, based on data collected by
UNAIDS, is reproduced with permission from reference (24). C Lippincott Williams & Wilkins,
2001.
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Figure 2. Targets for HIV entry inhibitors.
The four major targets in the Env-mediated HIV fusion pathway and the experimental drugs and
monoclonal antibodies (mAb) that block progression through this pathway are depicted. The Env
protein is depicted as in Chapter 1, Figure 2. Drugs and antibodies can prevent virus attachment,
gpl20-binding to receptor or coreceptor, or gp41 conformational transitions. The conformation
of gp4 1 in the prehairpin intermediate (with the N-HR and C-HR regions labeled N and C,
respectively) is unknown. The monoclonal antibody 2G12 binds carboyhdrate moieties on gpl20
and nonspecifically interferes with viral entry. The gp4 l-binding mAbs 2F5, 4E10, and Z13
preferentially recognize the native gp41 ectodomain, but do not interfere with receptor
attachment. Therefore, they are placed at the 'six-helix bundle transition' step, since they likely
inhibit gp41 conformational changes during fusion.
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Figure 3. gp120 subdomains.
A diagram structure ofgp 120 is shown. The sequence is based on a macrophage-tropic primary
isolate, JRFL. Glycosylation sites (high mannose, complex, or unknown) are indicated by
branched or U-shaped structures and the key CD4-binding residues are indicated with by a (*).
Modified and reprinted with permission from reference (5). American Society for
Microbiology, 2000.
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APPENDIX 1
gp41 GLYCOSYLATION
109
The N-linked glycans on gp41 are located at positions 611, 616, 624, 637, and 674 (numbered
according to the HXB2 strain). Of these, the glycosylation pattern at positions 616, 624, and 637
is well conserved among HIV-1, HIV-2, and SIV isolates (2) and all glycosylation sites except
the one at position 674 are highly conserved among HIV-1 isolates (4). gp41 is modified with
high-mannose carbohydrates (1) (in contrast, about half the oligosaccharides on gp120 are high-
mannose oligosaccharides, while the remaining half contains primarily complex, branched
structures with a few hybrid oligosaccharides. The type of glycan modification can vary,
however, when different cell lines are used for Env biosynthesis (7)). Site-directed mutations that
disrupt the canonical glycosylation sequence (Asn-X-Ser/Thr) at all five gp41 sites have been
made, and their effects are summarized here.
Johnson and colleagues mutated the four conserved asparagine residues (positions 611,
616, 624, and 637) to glutamine, both singly and as double, triple, or quadruple mutants. Single
glutamine substitutions at each of these positions showed only minor differences in expression
and processing using 293T cells and no significant effect on viral replication in human and rhesus
monkey T cell lines, as well as in rhesus peripheral blood mononuclear cells (3). The quadruple
mutant showed increased shedding of gp 120 into the culture medium and a defect in viral
replication, perhaps due to the altered stability and fold of the native Env glycoprotein. A triple
mutant containing glutamine substitutions at positions 611, 616, and 624 exhibited reduced
replication in some human lymphocytes (CEMx174 cells) but not in others (C8166-45 cells).
Cell-cell fusion activity was assessed for a few combinations of mutants. Env lacking
oligosaccharides at positions 616 and 637, or at positions 611, 616, and 624, showed substantial
cell-cell fusion activity. Cells lacking all four N-glycans were severely fusion impaired, in
agreement with the viral replication studies. However, these studies suggest that removal of the
individual oligosaccharides at these four positions does not impair Env expression or gp41
function.
In a similar study, a triple mutant containing glutamine substitutions at positions 616,
624, and 637 exhibited expression levels were similar to wild-type, with precursor cleavage
slightly decreased (-90% of wild-type) (2). This triple mutant showed a pattern of
immunoreactivity with a panel of gp41 antibodies that was the same as wild-type Env, and was
capable of binding to CD4. The cell-cell fusion activity of this mutant was about 30% of wild-
type levels however, suggesting that the overall bulk and hydrophilicity of the oligosaccharide
moieties may specifically affect gp41 function as fusion progresses.
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Another group created mutations both at the Asn and the Ser or Thr of the canonical Asn-
X-Ser/Thr glycosylation sequence, to further test how removal of the oligosaccharide (and not the
substituted residue itself) affects gp41 function. Mutation ofAsn-611 to His or Ser-613 to Ala
resulted in normal expression and processing in COS-7 cells, and replication kinetics in SupT
cells that were similar to wild-type (4). These results further indicate that glycosylation at
position 611 is not essential to Env processing or viral replication. At position 624, Asn was
mutated to His, again without effect on processing or growth kinetics. The additional mutation at
position 626 was not studied. Substitution of Asn-616 to His showed a slight decrease in growth
kinetics, whereas the Ser-618 to Ala mutation caused an increase in gp120 shedding and very
little viral replication. Thus, while glycosylation at residue 616 may not be essential for gp41
function, the neighboring residues (Ser-618) may form important contacts with gp 120 in the
native state. Unlike the later result by Johnson et al (in 2001, see above), who mutated Asn-637
to Gn, this 1992 study showed that N637H had delayed viral replication kinetics in SupT host
cells. Viral reverse transcriptase activity was not detected in the culture media until day 27 post-
infection, versus day 10 for wild-type virus. A similar result was seen with T639V virions. Since
reduced viral replication was observed for both the N637H and T639V mutants, the lack of
glycosylation may be affecting gp41 function. However, it should be noted that some of the
effect of the N637H mutant may be due to the added histadine residue; a more conservative
change to glutamine (as in Johnson et al) has less potential to disrupt Env structure. Interestingly,
mutation of the least well-conserved site, N674H, showed no difference in migration of gp41 by
western blot when compared to wild-type (size differences were observed for all other
substitutions); therefore, it is likely that this site is not glycosylated in HXB2 Env.
Overall, these studies do not point to a critical role for individual oligosaccharides in
gp41 function. In most cases, cell surface expression of cleaved mutant Env is normal (at least by
western blot analysis), indicating that the gp41 oligosaccharides must not be essential for
stabilizing the native state. Furthermore, removal of individual N-glycans does not alter viral
replication kinetics. The effects are made more severe by creating double or triple mutants;
however, it is difficult to pinpoint the exact role of N-glycans in gp41 function with such
dramatic substitutions. Moreover, many of these studies assess only expression and processing,
and viral growth kinetics. The potential role of oligosaccharides in stabilizing gp41 or the six-
helix bundle structure has not been investigated until recently.
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Since the resolution of gp41 core x-ray structures in the late 1990s, gp41
structure/function studies have been performed with isolated N- and C-peptides. These peptides
lack N-linked glycans since their chemical synthesis has been difficult to achieve. Recently,
these methods have been improved and have been used to study the effect of glycosylation on the
inhibitory activity of a potent C peptide, C34.
C34 contains a single N-linked oligosaccharide, at position 637. Three versions of the
C34 glycopeptide were constructed, containing a monosaccharide, a disaccharide, or a native-like
high mannose oligosaccharide (6). C34 containing a single glycan moiety (N-acetylglucosamine
or GlcNAc) at position 637 was synthesized according to standard techniques. To make a native
N-linked glycopeptide, a high mannose oligosaccharide was transferred onto GlcNAc-C34 using
the Arthrobacter endo-f3-N-acetylglucosaminidase (Endo-A) enzyme and an oligosaccharide
donor (Man9GlcNAc2Asn). Endo-A transfers an intact oligosaccharide moiety (in this case,
Man9GlcNAc) to a GlcNAc-containing peptide. The exact linkage between the transferred
oligosaccharide and GIcNAc-C34 was confirmed by Endo-F1 treatment and HPLC analysis.
Placement of the oligosaccharide at residue 637 was confirmed by treatment with pronase (which
hydrolyzes peptide bonds) followed by chromatographic analysis. Using a similar method,
construction of a disaccharide-C34 peptide (called LacNAc-C34) was performed using the P3-1,4-
galactosyltransferase (GalT) enzyme.
The disaccharide and high-mannose versions of C34 were more soluble than the C-
peptide alone-presumably due the negative charge of the high-mannose moiety-although they
remained unstructured in solution.
The glyco-C34 peptides formed less stable six-helix bundle structures with the N36
peptide when compared to unglycosylated C34. Melting temperatures for the mono-, di-, and
high mannose C34/N36 complexes were 54, 56, and 51 C, compared to 62 °C for the wild-type
complex. These six helix structures were also less helical than wild-type (58, 58, and 47%,
respectively, compared to 96%). Despite these structural differences however, the modified C
peptides still retained potent antiviral activity. In cell-cell fusion assays, mono- and di-saccharide
C34 peptides had IC50 values comparable to wild-type (-1.3 nM compared to 1.1 nM). The high
mannose-C34 had an IC50 value of 7.7 nM. These results show that the added oligosaccharide
does not substantially affect binding of the C-peptide to the trimeric N core.
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These results indicate that glycosylation of the C-terminal region may destabilize the
N36/C34 gp41 core more than previously suggested with unglycosylated complexes. However,
the glyco-C34 peptides cause a severe decrease in helicity of the bundle, and the authors have not
analyzed the oligomeric state or looked at the aggregation of these peptide structures.
Furthermore, the in vivo data suggests that Env still retains normal function without an
oligosaccharide at position 637. Thus, it is possible that glycosylating C34 has a more
pronounced effect on the peptide model than it does on native Env. In the context of the
N34(L6)C28 peptide model, the stability of the cavity mutants presented in Chapter 3 may be
shifted by addition of the oligosaccharide, but there is no evidence that the severity of the cavity
mutants with respect to each other (i.e. the Gly < Ala < Phe < WT trend) would be affected.
The effects of other N-glycans on C-peptide or six-helix bundle stability have not been
studied. The longest C peptide in the gp41 core that has been obtained by limited proteolysis of
the ectodomain and biophysically characterized is C43 (5). This peptide spans HXB2 residues
624 to 666, and contains two N-linked glycosylation sites (624 and 637). Thus, it is likely that
the remaining two (or three, if residue 674 is glycosylated) gp41 glycosylation sites fall outside
the C-terminal helical region. If the C-helix were plotted on a helical wheel (although it does not
conform to a strict heptad repeat motif), Asn-624 would fall at the d position, presumably making
close contact with the N-helix. Asn-637 would be placed at the c position, suggesting that this N-
linked oligosaccharide would be displayed on the outer surface of the six-helix bundle structure.
The labile, metastable native structure and the low solubility of the Envelope protein
make it a difficult protein to study in its entirety. Thus, limited proteolysis experiments have
been used to identify and study minimal, stable subdomains. N34/C28 and the slightly longer
N36/C34 represent the minimal protease-resistant gp41 fragments. These peptides were derived
from proteolysis of longer N51/C43 and N62/C52 fragments (5), which tend to form protein
aggregates, especially in isolation. Addition of oligosaccharides to these peptides may destabilize
these core peptide structures, and may make them less amenable to biophysical characterization.
However, the fact that antibodies directed against C-peptides or the six-helix bundle do not have
broadly neutralizing capability may be due to the shielding effect of the oligosaccharides. Thus,
glycosylated six-helix bundles, perhaps with longer N-C peptides than those studied here, may
serve as better immunogens in vaccine studies.
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